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CD38 is a 42-45 kDa type-II transmembrane glycoprotein expressed in many tissues and 
cell types. CD38 is initially identified as an ectoenzyme capable of converting β-NAD+ to 
cyclic ADP-ribose (cADPR), a potent modulator of Ca2+-induced Ca2+-release via 
ryanodine-sensitive Ca2+ channel. CD38 displays activity as a cell surface receptor in 
lymphocytes and triggers a variety of responses including: cell proliferation, apoptosis, 
protein tyrosine phosphorylation, intracellular calcium mobilization, etc. CD38 knockout 
mice also exhibit marked deficiencies in antibody responses to T-cell-dependent protein 
antigens, suggesting that CD38 may play an important role in vivo in regulating humoral 
immune responses. The present study was to investigate differential protein expression in 
CD38 deficient splenic B cells using proteomic approach. Novel information on the 
changes in protein profiles in CD38 knockout mice may provide new insights into the 
functional roles of CD38 in B cells.  Mouse splenic B cells were isolated using magnetic-
activated cell sorting (MACS) and its purity was ascertained by flow cytometry. Proteins 
of purified splenic B cells were subjected to two-dimensional gel electrophoresis (2-DE) 
and differentially expressed protein spots were analysed by MALDI-TOF mass 
spectrometry. The differential expression status of the candidate proteins were further 
analysed by RT-PCR. A total of 17 differentially expressed proteins were identified in the 
present studies and some of them are consistent with a role of CD38 in cell survival 
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1.1 General Introduction of CD38 
CD38 was originally defined by Reinherz et al. (1980) in their pioneering work on T 
lymphocyte and thymocyte differentiation antigens. The gene encoding CD38 (denoted 
as cd38) has been cloned from normal lymphocytes, B and T cell lines (Jackson and Bell, 
1990). Furthermore, Katz et al. (1983) have reported that the CD38 gene is located on 
chromosome 4. Initial studies concentrated on the immunological aspects of CD38, but it 
subsequently attracted the interest of many scientists from distant areas of research. 
Various fields in molecular, cellular, marine and plant biology have subsequently 
intertwined with that of biochemistry, immunology and crystallography in the 
paradigmatic quest to solve the riddle of CD38.  
            
          Initially, CD38 was discovered to possess a unique distribution pattern, being 
predominantly expressed by progenitors and early hematopoietic cells. It was lost during 
maturation and re-expressed on activated lymphocytes such as B cells, T cells, dendritic 
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cells, and natural killer cells (Mehta et al., 1996). Due to the curious characteristics of its 
expression, CD38 was initially used as a phenotypic marker of differentiation in leukemic 
and normal blood cells.  Patients with B cell chronic lymphocyte leukemia (B-CLL) who 
were CD38 positive showed a shorter survival compared with those that were CD38 
negative (Durig et al., 2002; Thornton et al., 2004). CD38 was also used as a marker of 
progression of human immunodeficiency virus type 1 (HIV-1) infection. The decrease of 
CD38 expression on CD8+ T cells was a good indicator of the effectiveness of highly 
active antiretroviral therapy (HAART), and the decrease of CD38 expression on CD8+ T 
cells was an indicator of the disease progression (Autran et al., 1997; Roussanov et al., 
2000). Interest in CD38 has grown since the discovery that human CD38 has significant 
amino acid sequence similarly to a 29 kDa cytosolic ADP-ribosyl cyclase enzyme (States 
et al., 1992). It was previously isolated from the sea mollusc known as Aplysia 
californica (Lee and Aarhus, 1991). 
           
          Aplysia cyclase has been shown to catalyze the synthesis of cyclic ADP-ribose 
(cADPR) from NAD+ and cADPR was subsequently proven to have potent calcium 
mobilizing properties (Lee and Aarhus, 1991). As predicted by its homology with the 
Aplysia cyclase, CD38 was shown to have the ability to catalyze the conversion of NAD+ 
into cADPR as well. CD38 also possesses an ability to hydrolyze the cyclic nucleotide to 
ADP-ribose (ADPR), which the Aplysia cyclase does not have (Howard et al., 1993). In 
addition, agonistic monoclonal antibodies against CD38 could trigger a myriad of 
responses including cytokine release (Ausiello et al., 1995), tyrosine phosphorylation 
(Kirkham et al., 1994), cell proliferation (Funaro et al., 1990) and apoptosis (Zupo et al., 
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1994) in a variety of cell types. CD38 has been detected in humans, mice, and rats by 
Reinherz et al. (1980), Howard et al. (1993), and Koguma et al. (1994), respectively. 
 
1.2 Overall Structure of CD38  
CD38 protein, a 42-45 kDa transmembrane glycoprotein, has a short N-terminal 
cytoplasmic part (20 amino acids) and a long extracellular domain (Jackson and Bell, 
1990). The gene encoding CD38 (denoted as cd38) is localized on chromosomes 4 and 5 
in humans and mice (Ferrero et al., 1999; Ferrero et al., 2000), respectively. Nata et al. 
(1997) have revealed that cd38 comprises eight exons with no CAAT or TATA box 
sequences in the 5’-flanking region. In addition, they have identified a GC-rich region 
that may act as the promoter region in the regulation of CD38 expression.  CD38 has 300 
amino acid residues and hallmarks of a type II integral membrane protein, i.e. carboxy-
terminus out, amino-terminus in, with an architecture consisting of three regions: 
extracellular (257 amino acids), transmembrane (23 amino acids), and intracellular (20 
amino acids) (Jackson and Bell, 1990).  Rat and murine CD38 cDNA sequences share 
~75% homology with the human CD38 cDNA sequence (Harada et al., 1993).  
           
          Previously, an important clue to the crystal structure of the extracellular domain of 
CD38 came from the determination of the crystal structure of its related proteins, the 
Aplysia californica cyclase (Prasad et al., 1996) and CD-157 (Yamamoto-Katayama et al., 
2002).  Recently, Liu et al. (2005) have determined the crystal structure of the soluble 
extracellular domain of human CD38 to 1.9 Å-resolution (Figure 1). The final refined 
structural model contains two soluble human CD38 (shCD38) molecules in the 
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crystallographic asymmetric unit, and each of them consists of 252 residues. The C-
terminal tail (TSEI) and the N-terminal secretion sequence (KREAEAR) from the 
expression vector are disordered in both molecules. The overall structure of the shCD38 
molecule is an “L”-shaped molecule which can be divided into two separate domains. 
The N-terminal domain (residues 45–118 and 144–200) consists of a bundle of α helices 
(α1, α2, α3, α5, α6) and two short β strands (β1, β3); and the C-terminal domain (residues 
119–143 and 201– 300) is formed by a four-stranded parallel β sheet (β2, β4, β5, and β6) 
which is surrounded by two short helices (α4 and α7) and two long helices (α8 and α9) 
(Figure 1A). Two distinct domains are connected by a hinge region consisting of three 
peptide chains, including residues 118–119, 143–144, and 200–201. A disulphide bond 
(Cys119-Cys201), which is unique in CD38, and the other five pairs of disulphide bonds 
(Cys67-Cys82, Cys99-Cys180, Cys160-Cys173, Cys254-Cys275, and Cys287-Cys296) 
conserved in ADP-ribosyl cyclase family members further stabilize the relative 
conformations of two domains by linking peptides 118–119 and 200–201 together. The 
formation of the disulphide bond by residues Cys119 and Cys201 confirms the previous 
prediction that disulphide bond may be vital for the catalytic activity (Prasad et al., 1996).  
           
           The crystal structures of the Aplysia cyclase (Prasad et al., 1996) and CD-157 
(Yamamoto-Katayama et al., 2002) reveal head-to-head and tail-to-tail homodimers, but 
the two shCD38 molecules do not form a dimer in the crystal. The two molecules can be 
superimposed quite well, except for at the N-terminal region (Figure 1B), where the N-
terminus involved in lateral associations was observed to bend further toward its own C 
terminus.  If shCD38 were aligned against the dimeric structure of the Aplysia cyclase or 
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CD-157 (head-to-head and tail-to-tail), there would be substantial structural clashes 
between the two shCD38 molecules at the C-terminal regions. Therefore, if shCD38 were 
dimerized in the same fashion as that observed in the Aplysia cyclase and CD-157, there 
would be a significant structural rearrangement of the C-terminal region of shCD38. This 
suggests that soluble CD38 may not naturally form a dimer, or at least not in the same 
manner as that observed for the Aplysia cyclase and CD-157. Actually, there is evidence 
suggesting that the structure of the enzymatically functional shCD38 in solution may be a 
monomer. In addition, there are reports that the full length CD38 can form dimers on the 
cell surface, requiring structural contributions from the intracellular tail. Thus, shCD38 
might not form a functional dimmer in solution or in crystals in the absence of the 
transmembrane domain and the intracellular tail. The lateral intermolecular associations 
observed in the crystal might be artifacts formed by molecular aggregation or by the 
crystallographic packing force. That deglycosylation of shCD38 may alter its 
dimerization. The silencing of the four glycosylation sites is essential for crystallization. 
However, the mutation of these sites should not affect the dimerization of shCD38, since 
structural alignments of CD38 with the Aplysia cyclase and CD-157 reveal that the 
glycosylation sites in both CD38 and CD-157 do not take part in the formation of dimers. 
It is further supported by the fact that deglycosylation of CD-157 does not affect its 
dimerization (Yamamoto-Katayama et al., 2002) and that the Aplysia cyclase can still 
form functional dimers without glycosylation (Prasad et al., 1996). 
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 Figure 1 The Overall Structure of shCD38 
(A) Two views of a ribbon representation of the structure of shCD38 related by 90° 
rotation around a vertical axis. (B) Superimposition of the two shCD38 molecules. The 
N-terminal structures (in red) in two molecules are different due to the intermolecular 
interactions (Liu et al., 2005). 
 
 
1.3 Distribution of CD38 
CD38 was studied in great detail in hematopoietic cells and its expression was most 
appropriately termed ‘discontinuous’ (Jackson and Bell, 1990). In fact, CD38 expression 
is repeatedly switched on and off as bone marrow precursors develop into mature 
elements of the various lineages, thus CD38 is an ideal marker for identifying populations 
at specific developmental stages. For instance, the passage from primitive or 
uncommitted (CD34+/CD38-) to committed precursor (CD34+/CD38+) is marked by 
surface CD38 expression (Terstappen et al., 1991). CD38 also marks T lymphocyte 
ontogenesis and it has been shown that more than 80% of medullary thymocytes are 
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CD38+, activated T cells are strongly CD38+, whereas peripheral blood T cells are mostly 
CD38- (Malavasi et al., 1992). In B lymphocyte ontogenesis, more than 90% bone 
marrow B cell progenitors are CD38+ (Kumagai et al., 1995), circulating B cells are 
CD38- , whereas plasma cells are strong expressors (Malavasi et al., 1992). Usually, 
CD38 is easily detected on erythrocytes, natural killer cells, platelets, as well as in most 
circulating monocytes, but neutrophils and endothelial cells are negative for CD38 
(Zocchi et al., 1993; Drach et al., 1994; Ramaschi et al., 1996; Fernandez et al., 1998).  
           
          In the gut, where a large percentage of cells of the immune system are found, 
intraepithelial lymphocytes are CD38-, whereas the lamina propria cells are CD38+  
(Fernandez et al., 1998). In the kidney, proximal convoluted tubules are strongly CD38+, 
whereas weak expression of CD38 is detected in distal and collecting tubules. In cardiac 
and skeletal muscle, CD38 has been detected on the sarcolemma by 
immunohistochemistry (Fernandez et al., 1998). In the thyroid, intra-parenchymatous 
fibrous septa are also positive for CD38 (Fernandez et al., 1998). In neural cells, where 
CD38 is expressed on the dendritic and penkaryal cytoplasm of neurons by a granular 
staining profile, which suggests an association with intracellular organelles. These 
findings are confirmed in a neurological disease model, in which CD38 immunoreactivity 
is associated with neurofibrillary tangles, the histological hallmark of Alzheimer’s 
disease (Mizuguchi et al., 1995).  Many other common tissues, such as stomach, intestine, 
pancreas, spleen, prostate, thymus, liver and brain also express relatively high amounts of 
CD38 (Koguma et al., 1994). Further investigations have reported that CD38 is localized 
to the sinusoidal domain in the plasma membrane and the inner nuclear envelope of the 
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rat hepatocyte (Khoo and Chang, 2000; Khoo et al., 2000). In addition, the mRNA for 
CD38 in rats has been detected in the spleen, liver, heart, thymus, thyroid gland, adrenal 
gland, jejunum, and pancreatic islets (Koguma et al., 1994).  
 
1.4 Enzymatic activity of CD38 
CD38 can catalyze the synthesis of cADPR and NAADP, two structurally distinct Ca2+-
mobilizing molecules (Lee et al., 1997). CD38 is able to convert NAD+ to cADPR (Lee 
and Aarhus, 1991) as shown in Figure 2. Subsequently, it is shown that CD38 cyclizes 
nicotinamide guanosine dinucleotide (NGD), an analog of NAD with guanine 
substituting for the adenine group, to produce cyclic GDP-ribose (cGDPR), which is 
refractory to cADPR-hydrolase (Graeff et al., 1994). cGDPR is fluorescent and has an 
absorption spectrum different from both NGD+ and GDPR. Thus, it provides a 
convenient way for monitoring its enzymatic formation. It is applicable for assaying the 
cyclization recreation for crude tissue extracts and pure enzymes by using of NGD+ as 
substrate. It makes a useful diagnostic tool to distinguish CD38-like enzymes from 
degradative NADases (Graeff et al., 1994). CD38 also can efficiently use NADP as 
substrate and catalyze the exchange of the nicotinamide group of NADP with nicotinic 
acid to produce NAADP (Aarhus et al., 1995). The exchange reaction predominates at 
acidic conditions while, at neutral and alkaline pH, the enzyme mainly catalyzes 
cyclization (Aarhus et al., 1995).  
          
          CD38 not only can catalyze the reactions described previously, but also can 
catalyze the hydrolysis of cADPR to ADP-ribose (ADPR) and NAD to ADPR (Lee et al., 
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1997) as shown in Figure 2. Indeed, when CD38 is incubated with NAD, the main 
enzymatic product is ADPR and not cADPR (Zocchi et al., 1993; Howard et al., 1993).  
 
 
Figure 2 Enzymatic activity of CD38 
CD38, a 45-kDa transmembrane glycoprotein, is a bifunctional protein and has both 
ADP-ribosyl cyclase and cADPR hydrolase activities. ADP-ribosyl cyclase converts β-
NAD to cADPR that is converted to ADPR by cADPR hydrolase (Adapted from 
Deshpande et al., 2005). 
 
          In contrast to the minimal production of cADPR, CD38 is able to catalyze a highly 
efficient hydrolysis of cADPR to ADPR. Therefore, CD38 is more appropriately 
considered as a specific hydrolytic rather than synthetic enzyme for cADPR. In fact, 
CD38 is the only known enzyme that can specifically hydrolyze the glycosidic linkage 
between the anomeric carbon of the terminal ribose and the N1 of the adenine ring of 
cADPR to produce ADPR. Many other common hydrolytic enzymes, including NADase, 
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alkaline phosphatase and phosphodiesterase, cannot degrade cADPR (Takahashi et al., 
1995; Graeff et al., 1998).   
 
1.5 Regulation of CD38 
The expression of membrane CD38 can be modulated by certain pharmacological and 
physiological agents such as retinoic acid, cytokines, and lectins. These agents up-
regulate CD38 expression independently of the cell lineage used in all instances. A 
particular interest is the regulation of CD38 expression by retinoic acid. Generally, 
mature circulating myeloid cells do not express CD38, which cannot be induced with 
retinoic acid. However, immature myeloid cells in the bone marrow have relatively 
higher CD38 expression, which can be further enhanced by retinoic acid treatment 
(Drach et al., 1994). Furthermore, transformed myeloid leukemia cells (e.g., HL-60, NB4, 
KG-1) have detectable surface CD38 expression that can be quickly up-regulated with 
retinoic acid treatment. Femtomolar concentrations of retinoic acid can induce a rapid 
and large increase in CD38 mRNA and protein expression (Drach et al., 1993; Drach et 
al., 1994; Malavasi et al., 1994). Retinoic acid-induced CD38 expression is highly 
specific since other agents (e.g., dimethylsulfoxide) that can induce similar differentiation 
of HL-60 cells do not affect CD38 expression. Retinoic acid-induced expression of CD38 
is under the control of the retinoic acid receptor-alpha (RARα) type of nuclear receptors 
(Drach et al., 1994, Mehta et al., 1996). Moreover, this induction can be observed even in 
vivo in leukemia patients after administration of a single oral dose of retinoic acid (Drach 
et al., 1993). 
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          The cyclase activity of CD38 was found to be markedly stimulated by Cu2+, which 
subsequently led to the use of immobilized Cu2+ in a column chromatography step as an 
efficient method for the purification of CD38 (Zocchi et al., 1993). Later, it was reported 
that Zn2+ could stimulate the ADP-ribosyl cyclase activity of recombinant human CD38 
fused with a maltose binding protein (MBP-CD38) and native membrane-bound CD38 of 
HL-60 cells induced with retinoic acid (Kukimoto et al., 1996). However, such 
stimulation of the cyclase activity is in contrast to the inhibition of the apparent NAD+-
glycohydrolase activity of both MBP-CD38 and native membrane-bound CD38 by Zn2+. 
This was interpreted as a negative regulation of Zn2+ on the accessibility of a water 
molecule to the ADP-ribosyl-enzyme complex and it was accordingly ascribed to the 
inhibition of the hydrolase activity rather than to the stimulation of its ADP-ribosyl 
cyclase activity (Kukimoto et al., 1996).  
          
          In addition, it was reported that the cADPR hydrolase activity of CD38 was 
inhibited by adenosine triphosphate (ATP) (Takasawa et al., 1993). This finding is 
especially interesting when one considers the fact that ATP is a candidate for correlating 
glucose as a stimulus for insulin secretion in islet cells, while cADPR is generated by 
pancreatic islets as a result of glucose stimulation (Takasawa et al., 1993). Furthermore, it 
has been shown that Lys-129 of CD38 participates in cADPR binding and that ATP 
competes with cADPR for the binding site that results in the inhibition of the cADPR 
hydrolase activity of CD38 (Tohgo et al., 1997). Another study gives further credence to 
the fact that the cADPR hydrolase activity is a selective target for inhibitory mechanisms, 
resulting in the increase of cADPR concentrations (Genazzani et al., 1996). It had been 
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shown that ADPR was able to decrease cADPR degradation in sea urchin eggs and to 
potentiate the synthesis of cADPR from NAD+. This finding was closely reminiscent of 
the report that the accumulation of cADPR was preceded by the generation of ADPR 
from NAD+ in heart muscle homogenates (Meszaros et al., 1995).  
 
1.6 CD38 related calcium release 
Release of calcium from intracellular stores is one of the important signal transduction 
mechanisms that play a pivotal role in the regulation of numerous cellular functions 
(Berridge, 1997). There are two major mechanisms for Ca2+ release from intracellular 
stores (Mackrill, 1999): A. Calcium mobilization mediated through inositol trisphosphate 
(IP3). The binding of certain external ligands to surface receptors can activate 
phospholipase C, which will cleave the head group of phosphatidylinositol bisphosphate 
and produce IP3. IP3 will mobilize Ca2+ from intracellular stores upon binding to its 
specific receptor as shown Figure 3; B. Calcium mobilization mediated through Ca2+-
induced-Ca2+ release (CICR). This kind of mechanism has been well characterized in 
cardiac myocytes, where the influx of Ca2+ can itself activate further Ca2+ release from 
intracellular stores and is believed to be mediated through the ryanodine receptor as 
shown in Figure 3. 
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 Figure 3 Intracellular mechanisms of calcium release in cells  
The model describes 2 principal intracellular pathways of calcium mobilization in cells. 
Ligand (agonist) binding to its cognate G protein-coupled receptor results in production 
of inositol 1,4,5- trisphosphate (IP3), which causes sarcoplasmic reticulum (SR) calcium 
release. Calcium-induced calcium release (CICR) is brought about by activation of 
ryanodine receptor (RyR) channels by calcium and cyclic ADP-ribose (cADPR). Cellular 
activity, i.e., contraction, requires elevation of intracellular calcium. 8-Bromo-cADPR (8-
Br-cADPR) inhibits calcium release by cADPR through RyR channels. The mechanism 
by which stimulation of the G protein-coupled receptor causes activation of CD38 and 
production of cADPR is not clearly understood. The process by which extracellularly 
generated cADPR enters the cell to bring about intracellular calcium release is also not 
clearly understood. ADPR, ADP-ribose; PLC-β, phospholipase-β; DAG, 1,2-
diacylglycerol; PIP2, phosphatidylinositol 4,5-bisphosphate; IP3R, IP3 receptor; N, N-
terminal end; A, B, and Y, α, β, γ subunits of G protein (Adapted from Deshpande et al., 
2005). 
 
           Cyclic ADP-ribose (cADPR), a cyclic nucleotide derived from NAD+, is an 
endogenous modulator of the CICR mechanism in cells (Galione et al., 1991; Lee, 1993). 
It requires calmodulin (Tanaka and Tashjian, 1995) to activate calcium mobilization, and 
calcium itself acts as a co-agonist (Lee, 1993). Nicotinic acid adenine dinucleotide 
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phosphate (NAADP) is derived from NADP+ and is also a potent calcium-mobilizing 
agent of intracellular Ca2+-stores (Lee and Aarhus, 1995). The Ca2+-release mechanism 
activated by NAADP is pharmacologically different from that activated by either cADPR 
or IP3 (Lee and Aarhus, 1995; Chini and Dousa, 1996). The Ca2+-stores NAADP acts on 
can be separated by gradient fractionation from those sensitive to cADPR and IP3 (Lee 
and Aarhus, 1995), indicating a hitherto unknown Ca2+-signaling mechanism.  
 
1.7 CD38 in immune system  
The task of the human immune system is to recognize and dispose of foreign antigens, 
and invading organisms, including viruses, fungi, bacteria, protozoa, etc. There are two 
different mechanisms (natural and adaptive immunity) by which these tasks are 
accomplished. Natural, inborn immunity consists of the nonspecific complement system, 
macrophages and natural killer cells, and adaptive immunity is based on the ability of B 
and T cells to respond selectively and specifically to challenges by different antigens. 
CD38 and B cells 
B cells are small (6–10 µm), and they have a dense nucleus and little cytoplasm. B cells 
were discovered together with T cells in the early 1960s. They can be distinguished 
phenotypically by analysis of cell surface markers. In the bone marrow, hematopoietic 
stem cells differentiate into common lymphocyte progenitors (CLP), which can develop 
into mature B cells. During the pro-B cell and pre-B cell stages, CLPs differentiate into 
immature B cells, which can express surface immunoglobulins (sIg) (Figure 4). Immature 
B cells further differentiate into IgD- and IgM-expressing mature B cells. The majority of 
developing B cells (>75%) enter apoptosis during pre-B cell stages. These developing B 
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cells will not survive if there is inappropriate heavy chain gene rearrangement (positive 
selection); besides, immature B cells become apoptotic if their sIg (IgM) recognizes self 
antigens (negative selection). Therefore, all self-reacting antibody forms must be 
eliminated to avoid future adverse autoimmune reactions though foreign antigens should 
elicit a specific immune response (Ollila and Vihinen, 2005). 
           
          B cell receptor (BCR) consists of two heavy (H) and two light (L) chains connected 
by disulfide bonds. Each chain contains constant (C) and variable (V) regions. The H and 
L chain loci undergo gene segment rearrangements (somatic recombination) during B cell 
development (Figure 4). This results in an individual specific V domain within H and L 
chains so that each BCR is specific for a single antigen. Whether or not a particular 
antibody is soluble or bounds to the plasma membrane depends on the production of 
alternative primary RNA transcripts. H chain gene is rearranged during the pro-B cell 
stage and the Hµ chain is expressed in the cytoplasm. At the pre-B cell stage, the µ chain 
associates with a surrogate light chain and Igα and Igβ polypeptides, they together form a 
pre-B cell receptor (pre-BCR). The pre-BCR is able to transduce a signal into the cell that 
is vital for further B cell development. The L chain is then rearranged and the mature 
IgM is expressed on the cell surface. 
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 Figure 4 Genes related to B cell development  
The maturation steps and stages are shown at the top. The center shows changes in the 
expression of surface markers and proteins involved in gene rearrangements 
characteristic of different B cell developmental stages. The bottom of the figure depicts 
the gene rearrangement processes of the heavy and light chains of the IgM molecule 
(Adapted from Ollila and Vihinen, 2005). 
 
          CD38-mediated signaling augments BCR responses and is dependent on BCR 
expression, at least in mouse although the same mechanism has yet to be proven 
conclusively in human cells. The functional relationships between CD38 and BCR 
suggest that the signaling pathways utilized by CD38 and BCR may intersect (Lund et al., 
1996).  Stimulation of murine B cells with mAbs directed against the extracellular 
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domain of CD38 shows to induce a weak Ca2+ influx and proliferation of the B cells in 
the presence of the appropriate costimulators is followed. Anti-CD38 mAbs can up-
regulate B cell surface molecules including MHC class 11, LFA-1, and B7-2 (Lund et al., 
1995). Mouse and human B cells can be protected from apoptosis by anti-CD38 Abs 
(Zupo et al., 1994). Finally, it has been demonstrated that anti-CD38 Abs can inhibit 
human B lymphopoiesis in vitro (Kumagai et al., 1995). 
CD38 effects on T cells 
CD38 might play an important role in signaling from the observation that ligation of 
CD38 on T cell lines with certain anti-CD38 monoclonal antibodies induced activation 
and proliferation signals (Funaro et al., 1990). Subsequent experiments have revealed that 
this ligation is also able to induce the transcription of various cytokines including tumor 
necrosis factor-alpha, interleukin-1 (IL-1), and granulocyte-macrophage colony-
stimulating factor at levels similar to that obtained by triggering the T cell receptor CD3. 
However, the amounts of cytokines triggered in response to CD38 are different from 
those induced via CD3 (Ausiello et al., 1995). In addition, it has been reported that 
CD38-dependent activity of T cell line requires the parallel expression and function of 
TCR and its corresponding signaling molecule, CD3 (Morra et al., 1998). 
           
           CD38-mediated cytokine induction does not require either the addition of antigen-
presenting cells or T cell proliferation. Furthermore, it has been observed that signaling 
through CD38 in a T cell acute lymphoblastic leukemia (Jurkat) cell line lead to calcium 
mobilization kinetics that are different from those induced through the T cell receptor 
CD3 (Deaglio et al., 1996). This indicates that certain signaling pathways mediated by 
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CD38 are distinct from that activated by CD3. It has been shown to be able to trigger 
signaling pathways that lead to activation and proliferation by incubation of Jurkat cells 
or peripheral blood T cells with the agonistic anti-CD38 mAb, IB4 (Funaro et al., 1990), 
which also down-modulates the TCR/CD3 complex, increases intracellular calcium levels, 
up-regulates CD5, CD28, CD69 and CD95 as well as cell death by apoptosis (Morra et al., 
1998). CD38 ligation is also able to induce tyrosine phosphorylation of a variety of 
cellular substrates including phospholipase C-γ1, ζ-associated protein (ZAP)-70, 
extracellular signal-regulated protein-kinase-2 (Erk-2), c-cbl, Shc, and CD3-ζ. In 
comparison, the phosphorylation induced by anti–CD3 is both quantitatively and 
qualitatively distinct (Zubiaur et al., 1997). 
CD38 effects on myeloid cells and natural killer cells  
CD38 ligation on retinoic acid-induced human myeloid leukemia (HL-60) cells results in 
an increase of superoxide generation by G protein-coupled receptors (Tsujimoto et al., 
1997) and also causes the tyrosine phosphorylation of c-cbl, syk, HS1 and FcγRII. 
Furthermore, it has been reported that the cytotoxic activity of peripheral blood natural 
killer cells mediated by granule exocytosis can be triggered by anti-CD38 upon activation 
with IL-2 (Ferrero and Malavasi, 1999).   
 
1.8  CD38 in human diseases 
CD38 seems to be involved in a myriad of immune-regulatory functions in a multitude of 
hematopoietic cell populations and it is no surprise to know that there are a lot of recent 
discoveries regarding the association of CD38 with certain human diseases. Zupo et al. 
(1996) have reported that B-chronic lymphocytic leukemia (B-CLL) patients can be 
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subdivided into two different groups, CD38-positive type B-CLL and CD38-negative 
type B-CLL, depending on the presence or absence of CD38 on the malignant cells. 
Pittner et al. (2005) have reported that CD38 is a marker of a more recently activated 
CLL B cells. They may explain the clinical and biological difference between CD38-
positive type B-CLL and CD38-negative type B-CLL.  In addition, exposure of these 
malignant cells with high CD38 expression in vitro to anti-µ antibodies results in calcium 
mobilization followed by apoptosis, while neither of these phenomena is observed in the 
CD38-negative cells. Together, these data suggest that CD38 expression may be a marker 
for B cells that have a propensity for apoptosis. This conclusion is in agreement with the 
fact that the malignant cells of Burkitt’s lymphomas (Cutrona et al., 1995) and normal 
germinal center B cells (Zupo et al., 1994), which express abundant CD38, are prone to 
apoptosis.  
           
          More than two decades ago, it was observed that CD8+ T cells had an increased 
expression of CD38 in HIV-1-infected patients. Subsequently, it was shown that low 
CD4+ T cells counted in HIV-1-infected patients (Bofill et al., 1996). Thus, some 
researchers used CD38 as a useful and reliable prognostic marker for the pathological 
development of AIDS (Liu et al., 1998). Recently, Onlamoon et al. (2005) found that the 
most discriminating change between healthy donors and HIV-1-infected patients was the 
increased frequency and density of CD38 expression by CD3+CD8+ T cells. 
           
          CD38 was shown to play a pivotal regulatory role in the murine model with regards 
to insulin secretion through calcium mobilization of cADPR-sensitive stores (Kato et al., 
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1995). The study on the causal relationship between insulin release and CD38 was 
extrapolated to man where it was shown that anti-CD38 autoantibodies might be playing 
an important role in impaired glucose-induced insulin secretion (Ikehata et al., 1998). 
Moreover, Yagui et al. (1998) showed that the Arg140Trp mutation on CD38 might be 
responsible for the development of Type II diabetes mellitus through the impairment of 
glucose-induced insulin secretion. Kato et al. (1999) corroborated the growing evidence 
that CD38 was essential in intracellular Ca2+-mobilization via cADPR for the secretion of 
insulin through experiments using CD38 knockout mice.  Recently, Mallone et al. (2002) 
showed that anti-CD38 autoantibodies prevalence among new-onset Type I diabetic 
patients was lower than previously found in long-standing Type I diabetes, suggesting a 
late appearance of these autoantibodies. 
            
          X-linked agammaglobulinemia (XLA) or Bruton’s disease is characterized by the 
failure of differentiation and maturation of the B lymphocyte lineage at the pro-B-cell 
stage, leading to absent or low levels of circulating immunoglobulins (Liu et al., 2006). 
The gene responsible for XLA is Bruton’s tyrosine kinase (Btk) that encodes a protein 
sharing similar features with the src tyrosine kinase family. The precise function of Btk is 
currently unknown, although other cytoplasmic tyrosine kinases are thought to be 
involved in mediating signal transduction after cell activation (Bolen, 1993). Previous 
data derived from X chromosome-linked immunodeficient mice (Xid, the homologue of 
human XLA) indicated a close relationship between Btk and CD38. Purified splenic B 
cells from Xid mice were totally unresponsive to stimulation via CD38 in the presence of 
accessory stimuli, even though the catalytic functions and expression of CD38 on these 
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cells were comparable to wild type B cells (Santos-Argumedo et al., 1995). It was also 
reported that B cells from Xid mice did not respond to signaling through CD38 and, most 
important, that there was complete absence of tyrosine phosphorylation of Btk (Kikuchi 
et al., 1995). Therefore, it is believed that CD38 plays a key role in the life of B cells, 
although a direct physical association between Btk and CD38 has not been observed 
(Santos-Argumedo et al., 1995).     
           
          The poor prognosis of myeloma has prompted the use of alternative treatments 
including hormonotoxins and immunotoxins. However, the use of modified toxins 
conjugated to hormones or antibodies to surface molecules on myeloma cells is hampered 
by the lack of specific targets on plasma cells. An interesting alternative method used the 
increased expression of CD38 in these myeloma cells as a target for the in vitro and in 
vivo depletion of tumor cells (Ellis et al., 1995). Stevenson et al. (1991) reported that 
recombinant anti-CD38 mAb with a murine anti-CD38 variable region mounted on a 
human IgG Fc sequence cross-linked to a modified ricin molecule. An alternative 
approach entailed the use of bispecific antibodies for the delivery of other toxins in 
human acute T cell lymphoblastic leukemia through CD7 and CD38 as target molecules 
(Flavell et al., 1992). CD22 and CD38 as target molecules for bispecific antibodies in the 
immuno-treatment of lymphoma were also used (French et al., 1995). Moreover, Flavell 
et al. (1995) reported that a similar approach was tested for the treatment of B cell 
lymphoma using anti-CD-19 and anti-CD38-saponin immunotoxins. The results obtained 
from these studies suggested that anti-CD38-toxin immunoconjugates might prove to be 
useful therapeutic tools in the treatment of myeloma, lymphoma and leukemia. In each 
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case, the toxic potential on tumor cells with higher expression of CD38 was significant, 
whereas effects on normal peripheral blood cells or hematopoietic progenitor cells were 
negligible (Mehta et al., 1996).  Recently, Bolognesi et al. (2005) reported that it was 
reasonable to propose a clinical use of the IB4/saporin-S6 for ex vivo purging of 
unwanted cells (e.g. CD38+ neoplastic cells from a Non Hodgkin Lymphoma patient) or 
for loco-regional therapies of CD38+ tumors. 
 
1.9 Features of mice and generation of CD38 knockout mice  
CD-1 mice were from The Jackson Laboratory (Bar Harbor, Maine, USA). CD-1 mice 
were derived from Swiss mice that have a high degree of genetic variation and selected 
for robust reproduction.  CD-1 mice were an outbred strain and used as wild type mice in 
this project. CD38 knockout mice were originally a generous gift from Dr. Hiroshi 
Okamoto. CD38 knockout mice were generated by the following method (Figure 5) 
(Kato et al., 1999). A 15-kbp mouse genomic DNA (BamHI-BamHI) fragment with the 
first exon of the CD38 gene (DDBJ/EBI/GenBankTM accession number AB016868) was 
cloned from a TT2 embryonic stem (ES) cell genomic library. The BamHI site and the 
loxP sequence were introduced into the HindIII site located 0.5 kbp 59 upstream of exon 
1, which contains the translation initiation site. A neomycin resistance gene with a PGK-
1 promoter but without a poly(A)+ addition signal was inserted into the HindIII site 
located 0.6 kbp 39 downstream of exon 1. A diphtheria toxin A (DTA) fragment gene 
containing a MC1 promoter was ligated on the 39 terminus for negative selection. The 
targeting vector was designated as pCD38-loxP-DTA. 
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 Figure 5 Disruption of the CD38 gene in mice  
Schematic representation of the CD38 targeting vector, mouse CD38 gene, targeted allele, 
and deleted allele. Neomycin resistance gene (NEO), DTA gene, and the loxP sequences 
are shown by open box, filled box, and triangles, respectively. Positions of probes used 
for Southern blot analyses with BamHI are also shown. B, BamHI; H, HindIII; N, NotI; P, 
PstI; S, SacI; Xb, XbaI; Xh, XhoI (Adapted from Kato et al., 1999). 
 
 
          TT2 embryonic stem (ES) cells were transfected with the targeting vector, NotI-
cleaved pCD38-loxP-DTA. G418-resistant clones were analyzed using Southern blotting. 
The correctly targeted ES cells were injected into eight-cell embryos of CD-1 mice for 
producing germ-line chimeras. 2 µg/ml of the Cre-containing plasmid (pBS185; Life 
Technologies) was microinjected into the male pronuclei of fertilized eggs obtained by 
mating between the male chimera and (C57BL/6J 3 DBA) F1 female mice. Some of the 
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newborn mice (F1) were found to carry the deleted allele (5.3-kbp BamHI-BamHI 
fragment) lacking both CD38 exon 1 and neo cassette. Wild type and CD38 knockout 
mice used in this project were the littermates intercrossed between male and female 
heterozygotes that had been backcrossed to CD-1 mice for three-four generations. 
 
1.10 Objective of the project 
The function of CD38 in B cells is not clear yet. The objective of this project is to 
characterize or provide new insights into the functional roles of CD38 in B cells. To 
investigate this, CD38 knockout and wild type mice were generated. B cells were isolated 
from CD38 knockout and wild type mice for determination of protein and mRNA levels. 
The study was done by using a variety of methods: 
1) Magnetic-activated cell sorting (MACS), which  was used to isolate B cells from 
spleens of both wild type and CD38 knockout mice; 
2) Flow cytometry , which was used to determine the purity of isolated B cells from 
spleens, together with related antibodies; 
3) Two-dimensional electrophoresis (2-DE), which was used to compare protein 
profiles of B cells from wild type and CD38 knockout mice; 
4) MALDI-TOF mass spectrometry (MALDI-TOF MS), which was used to identify 
selected proteins that had significantly different expression in B cells between 
wild type and CD38 knockout mice;  
5) Reverse transcript-polymerase chain reaction (RT-PCR), which was used to check 
whether or not mRNA expression levels would be consistent with protein 
expression levels. 
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Materials and Methods  
 
2.1 Materials 
2.1.1 Chemicals and Reagents 
Standard analytical grade laboratory chemicals for the preparation of general reagents 
were obtained from Merck, Darmstadt, Germany; Sigma Chemicals Co., St. Louis, MO, 
USA. Special reagents were obtained from: 
           
            Bio-Rad, Hercules, CA, USA.
 Bio-Rad Protein Assay Kit 
 Coomassie Blue 
 Polyacrylamide Gel Reagents 
 Bromophenol Blue 
  
             
            Sigma-Aldrich, St. Louis, MO, USA.
 β-mercaptoethanol 
            BSA 
 Sodium Dodecyl Sulfate (SDS) 
            Iodoacetamide 
            Thiourea 
            Sodium Thiosulfate 
            HEPES 
            Hanks' Balanced Salt Solution (HBSS) 
            RPMI-1640 Medium 
 25
            Phosphate Buffered Saline (PBS) 
  
            
            GE Healthcare, Buckinghamshire, England.
            Immobiline DryStrip pH 4-7, 18 cm  
            Immobiline DryStrip pH 6-11, 18 cm 
            IPG Buffer pH 4-7 
            IPG Buffer pH 6-11 
            Urea 
            PlusOne™ Glycerol 
            Dithiothreitol (DTT) 
            CHAPS 
            Tris 
            
            Applied Biosystems, Cheshire, UK.
            SYBR Green PCR Master Mix 
 
            
            Invitrogen, Carlsbad, CA, USA.
            TRIzol Reagent 
            Superscript II RNase Reverse Transcriptase 
 
 
            Roche, Penzberg, Germany.
 RNase-free DNase 1  
 
              
            Promega, Madison, WI, USA.
 PCR Reagents 




Miltenyi Biotec, Bergisch Gladbach, Germany. 






Fetal Bovine Serum 
 
 
Jackson ImmunoResearch Laboratories, Baltimore, PA,USA. 












2.1.2 Instruments and General Apparatus 
1. Eppendorf® Refrigerated Multipurpose Centrifuge 5810 R (Eppendorf-
Netheler-Hinz GmbH, Hamburg, Germany) 
2. Beckman DU® 640B Spectrophotometer (Beckman Instruments Inc., Palo Alto, 
CA, USA) 
3. Biometra Thermocycler (Biometra, Goettingen, Germany) 
4. Constant Voltage Power Supply Model 200/2.0 (Bio-Rad, Hercules, CA, USA) 
5. FluoView 300 Laser Scanning Microscope (Olympus, Melville, NY, USA)  
6. Centricon-3 Filters (Millipore, Bedford, MA, USA)  
7. LS 50B Luminescence Spectrophotometer (Perkin Elmer, Foster, USA) 
8. LS Separation Columns (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) 
9. Eppendorf® Centrifuge 5415 R (Eppendorf-Netheler-Hinz GmbH, Hamburg, 
Germany)  
10. Pre-Separation Filters (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) 
11. MACS Multistand (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) 
12. LS Column Adapter (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany)  
13. GS-800 Calibrated Imaging Densitometer (Bio-Rad, Hercules, CA, USA)  
14. PDQuestTM Software (Bio-Rad, Hercules, CA, USA)  
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15. Voyager DE-STR Biospectrometry Workstation (Applied Biosystems, Foster 
City, CA, USA) 
16. MASCOT software (Matrix Science, London, UK)  
17. CyAnTM ADP Flow Cytometer (DAKO, Glostrup, Denmark)       
18. Summit v.3.3 software (DAKO, Glostrup, Denmark)       
19. Ettan™ IPGphor™ I IEF System and Accessories (GE Healthcare, 
Buckinghamshire, England) 
      20. Ettan™ DALT six and twelve Large Vertical System and Accessories (GE 
Healthcare, Buckinghamshire, England) 
      21. Immobiline DryStrip Reswelling Tray, for 7-24 cm IPG strips (GE Healthcare, 
Buckinghamshire, England) 
      22. Savant SVC100H Speed-Vac (GMI, Ramsey, MN, USA) 
      23. Oven Model LO-201C (Grieve Corporation, Round Lake, IL, USA) 




CD38 knockout mice were originally a generous gift from Dr. Hiroshi Okamoto. CD-1 
mice were from The Jackson Laboratory (Bar Harbor, Maine, USA) and were used as 
wild type mice. CD-1 mice were an outbred strain and derived from Swiss mice that have 
a high degree of genetic variation and selected for robust reproduction. Male wild type 
and CD38 knockout mice used in this project were intercrossed between male and female 
heterozygotes that had been backcrossed to CD-1 mice for three-four generations. Both 
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male wild type and CD38 knockout mice were used at ~8 wk of age. Animals were 
housed in specific pathogen-free conditions and under a 12:12 h light/dark cycle with free 
access to food and water. Six wild type mice were used as controls and compared with 
six CD38 knockout mice. Animal experiments were performed in accordance with the 
Institutional Guidelines for Animal Care and Use of the National University of Singapore.  
 
2.3 Isolation of Splenic B Cells 
Total splenic cell suspensions were prepared from spleens of ~8 wk old wild type and 
CD38 knockout mice according to the basic protocol of preparation of cell suspensions 
from spleen (3.1.2, Current Protocols in Immunology, 2000). Before counting the total 
number of lymphocytes in suspensions of total splenic cells, red blood cells were 
removed with ACK lysing buffer containing 0.15 M NH4Cl, 10.0 mM KHCO3, 0.1 mM 
Na2EDTA. Total splenic cells were spun for 10 minutes at 200×g in a low-speed 
centrifuge. After supernatants were discarded, total splenic cells were washed with 
Hanks' Balanced Salt Solution (HBSS) containing 5.4 mM KCl, 0.3 mM Na2HPO4·7H2O, 
0.4 mM KH2PO4, 4.2 mM NaHCO3, 1.3 mM CaCl2, 0.5 mM MgCl2·6H2O, 0.6 mM 
MgSO4, 137 mM NaCl, 5.6 mM D-glucose, 4ºC and spun at 200×g in a low-speed 
centrifuge. After supernatants were removed, total splenic cells were washed with HBBS 
and resuspended in RPMI-5 medium containing 5% FBS, 2 mM L-glutamine, 100 U/ml 
penicillin, 100 µg/ml streptomycin sulfate in RPMI 1640 medium for cell counting (3.1.3, 
Current Protocols in Immunology, 2000).  
            
          Total splenic cells were spun down for 10 minutes at 300×g and resuspended in 40 
µl of  buffer containing 0.5% bovine serum albumin, 2 mM EDTA in PBS (pH 7.2, 
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degassed, 4º-8ºC) per 107 total cells. 10 µl of Biotin-Antibody Cocktail containing 
cocktail of biotin-conjugated monoclonal antibodies against CD43 (Ly-48) (rat IgG2a), 
CD4 (L3T4) (rat IgG2b), Ter-119 (rat IgG2b) as well as Anti-Biotin Microbeads per 107 
total cells was added to total splenic cells. Cell suspensions were mixed well immediately 
and incubated for 10 minutes at 4º-8ºC. Then 30 µl of buffer containing 0.5% bovine 
serum albumin, 2 mM EDTA in PBS (pH 7.2, degassed, 4º-8ºC) and 20 µl of Anti-Biotin 
MicroBeads that were colloidal superparamagnetic MicroBeads conjugated to a 
monoclonal anti-biotin antibody (clone: Bio3-18E7.2; mouse IgG1) per 107 total cells 
were added to total splenic cells. Cell suspensions were mixed well immediately and 
incubated for 15 minutes at 4º-8ºC. Subsequently, total splenic cells were washed with 
buffer containing 0.5% bovine serum albumin, 2 mM EDTA in PBS (pH 7.2, degassed, 
4º-8ºC). 10-20× labeling volumes of buffer containing 0.5% bovine serum albumin, 2 
mM EDTA in PBS (pH 7.2, degassed, 4º-8ºC) were added and mixed well immediately 
and centrifuged at 300×g for 10 minutes. After supernatants were discarded completely, 
cell pellets were resuspended in 500 µl of buffer containing 0.5% bovine serum albumin, 
2 mM EDTA in PBS (pH 7.2, degassed, 4º-8ºC) per 108 total cells.  
             
           MACS Column (LS Column) was placed in the magnetic field of a suitable MACS 
Separator (MidiMACS with Column Adapter). Column was prepared by rinsing with 3 
ml of buffer containing 0.5% bovine serum albumin, 2 mM EDTA in PBS (pH 7.2, 
degassed, 4º-8ºC). Cell suspension from each mouse was applied onto the column and 
cells were allowed to pass through.  Effluent was collected in a 15-ml tube as fraction 
with unlabeled cells, representing the enriched B cell fraction.  The column  was washed 
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with 4×3 ml of buffer containing 0.5% bovine serum albumin, 2 mM EDTA in PBS (pH 
7.2, degassed, 4º-8ºC)  and entire effluent was collected in the same tube according to the 
manufacturer’s protocol (Miltenyi Biotec, Bergisch Gladbach, Germany). MACS 
Columns should be changed one by one when cell suspensions were changed from 
different mice. Consequently, splenic B cells from both wild type and CD38 knockout 
mice were enriched using B Cell Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, 
Germany). Both Biotin-Antibody Cocktail and Anti-Biotin Microbeads are included in B 
Cell Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany). 
 
2.4      Flow Cytometry 
To test the purity of isolated splenic B cells, one sample from total splenic cells and two 
samples from isolated splenic B cells were tested by flow cytometry. First, two aliquots 
of total splenic cells were stained with Biotin-Antibody Cocktail and Anti-Biotin 
Microbeads, both of which were included in B Cell Isolation Kit. The Biotin-Antibody 
Cocktail contains the biotin-conjugated antibodies against CD43 (Ly-48), Ter-119, and 
CD4 (L3T4), as well as Anti-Biotin Microbeads, which were colloidal superparamagnetic 
MicroBeads conjugated to a monoclonal anti-biotin antibody (clone: Bio3-18E7.2; mouse 
IgG1). Each aliquot contains about 107 cells.  Splenic B cells were isolated from one 
aliquot using B Cell Isolation Kit.  Then a part of isolated splenic B cells were aliquoted 
from these isolated splenic B cells. This part of isolated splenic B cells was not stained 
with Anti-Biotin-APC and CD45R (B220)-PE, whereas one aliquot of total splenic cells 
and one aliquot (the left part) of isolated splenic B cell were stained with Anti-Biotin-
APC and CD45R (B220)-PE. The part of isolated splenic B cells that was not contained 
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with Anti-Biotin-APC and CD45R (B220)-PE was resuspended in 100 µl of buffer 
containing 0.5% bovine serum albumin, 2 mM EDTA in PBS (pH 7.2, degassed, 4º-8ºC) 
and used as a control for analysis by flow cytometry. 
            
          10 µl of CD45R (B220)-PE (Miltenyi Biotec, Bergisch Gladbach, Germany), 
which contained monoclonal CD45R conjugated to R-phycoerythrin (PE), was added to 
each aliquot that contained isolated splenic B cells or total splenic cells. Cell suspensions 
in both aliquots were mixed well immediately and incubated for 10 minutes in the dark at 
4º-8ºC. Subsequently, cells in both aliquots were washed by adding 1-2 ml of buffer 
containing 0.5% bovine serum albumin, 2 mM EDTA in PBS (pH 7.2, degassed, 4º-8ºC) 
and centrifuged for 10 minutes at 300×g. After supernatants were removed completely, 
10 µl of Anti-Biotin-APC (Miltenyi Biotec, Bergisch Gladbach, Germany), which 
contained Anti-Biotin antibody conjugated to APC, was added to each aliquot. Cell 
suspensions in both aliquots were mixed well immediately and incubated for 5 minutes in 
the dark at 4º-8ºC.  Cells in both aliquots were washed by adding 1-2 ml of buffer 
containing 0.5% bovine serum albumin, 2 mM EDTA in PBS (pH 7.2, degassed, 4º-8ºC) 
and then cell suspensions in both aliquots were centrifuged at 300×g for 10 minutes. 
After supernatants were discarded completely, cells in each aliquot were resuspended in 
100 µl of buffer containing 0.5% bovine serum albumin, 2 mM EDTA in PBS (pH 7.2, 
degassed, 4º-8ºC) for analysis by flow cytometry using CyAnTM ADP Flow Cytometer 




2.5   Sample Preparation 
Splenic B cells from wild type and CD38 knockout mice were isolated and solubilized in 
a lysis buffer containing 8 M urea, 2 M thiourea, 4% CHAPS, 0.8% Pharmalyte, 65 mM 
DTT, protease inhibitor cocktail, 5 µg/mL DNase I and 20 µg/mL RNase A. The lysates 
were centrifuged at 12 000×g for 15 minutes and transferred the supernatants into new 
tubes. After protein concentration assay, aliquots (100 µg per tube) of the supernatants 
were stored at -80ºC until further use. 
 
2.6    Protein Concentration Assay 
Five different dilutions of BSA (Sigma-Aldrich, St. Louis, MO, USA) between the ranges 
of 0.2 to 1 mg/ml using Milli-Q grade water as diluent were prepared. 12 µl of Milli-Q 
grade water + 3 µl of each standard and unknown sample solution were added into clean, 
dry 96-wells plate by pipettor. For the blank or control, 12 µl of Milli-Q grade water + 3 
µl of a lysis buffer containing 8 M urea, 2 M thiourea, 4% CHAPS, 0.8% Pharmalyte, 65 
mM DTT, protease inhibitor cocktail, 5 µg/mL DNase I and 20 µg/mL RNase A was 
pipetted into the same 96-wells plate instead. 200 µl of dye reagent was added into each 
sample solution. The respective mixtures were then incubated at room temperature for 
10-12 minutes and absorbance at 595 nm was measured. A standard calibration curve of 
absorbance against BSA was plotted. The protein concentrations of unknown samples 
were calculated according to both standard calibration curve and their absorbance data. 
 
2.7 Two-Dimensional Electrophoresis (2-DE)  
2.7.1 Rehydration 
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Reswelling tray and strip holders were washed and dried in air. 2.8 mg DTT was added to 
per ml rehydration solution, which contained 8 M Urea, 2% CHAPS, 0.5% IPG buffer 
(pH 4-7), 2 M Thiourea, 10% Isopropanol, 5% Glycerol, 0.018 M DTT, 0.0005% 
Bromophenol blue. 80 µg of protein was taken out per sample and put into a 1.5-ml clean, 
dry tube. Rehydration solution was added up to 350 µl per tube. The 350 µl solution was 
mixed well and put into each strip holder. Strip was taken out and the cover membrane 
was tore. Strip was put into reswelling tray with gel facing down. ~3 ml of mineral oil 
was added onto each strip. It should be incubated for more than 12 hours for rehydration. 
2.7.2 First-Dimension: Isoelectric Focusing (IEF) 
An IPGphor protocol was programmed as: 200V×0.5 hr, 500V×1 hr, 4000V×1.5 hrs, 
8000V×6 hrs for IEF. The rehydrated strips were taken out from reswelling tray and the 
non-gel faces of strips were washed with Milli-Q grade water. The strips were dried with 
tissue paper. The strips were put into the strip holders with gel facing up and electrode 
paper pads were prepared and soaked with water on glass. The pads were put in both ends 
and placed the electrode above the gel. ~3 ml of mineral oil was added as cover fluid and 
IEF was started. After completing IEF, final parameters (v, vhrs, µA, hrs) were recorded. 
The strips were taken out of the strip holders and put into a stack. The strips were stored 
at -80ºC refrigerator.  
2.7.3 Cast Gel (20 cm gel, 12%) 
Glass plates were cleaned with 100% alcohol and glass stack was set up tightly. Gel 
solution containing 1.5 M Tris-HCl (pH8.8), 10% SDS, 30% Acrylamide, 0.05% 
TEMED, 2.2 mM Ammonium persulfate (APS) was prepared. TEMED and APS were 
added at last. The gel solution was gently stirred for avoiding bubbles and then 
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immediately poured into stack up to 1.5 cm from the top (80 ml/per gel). 2 ml 
isopropanol per gel was added immediately and waited for more than 1.5 hrs for gel 
polymerization. Isopropanol was emptied before running second-dimension: SDS-PAGE. 
2.7.4 Second-Dimension: SDS-PAGE  
~3 L of 1× SDS running buffer (totally need 4-4.5 L of 1× SDS running buffer) 
containing 25 mM Tris-Base, 192 mM Glycine, 0.1% (w/v) SDS was added to tank and 
the cooler was opened to 15ºC. SDS-PAGE gels were run in a temperature of 15ºC. The 
equilibration solution containing 50 mM Tris-Cl (pH8.8), 6 M Urea, 30% (v/v) Glycerol, 
2% (w/v) SDS was thawed in air and a heater was opened to melt agarose for about 10 
minutes.  SDS-PAGE gels were taken out of the stack and the unit was set up. The strips 
were taken from -80ºC refrigerator to thaw. 120 mg/12 ml of DTT was added to an 
equilibration solution tube as a type-I solution and 300 mg/12 ml of Iodoacetamide (IAA) 
was added to an equilibration solution tube as a type-II solution. Agarose was taken out 
to cool slightly down to 40-50ºC. Strips were rinsed in 1× SDS running buffer and then 
placed into glasses. Strip was contacted with SDS-PAGE gel to avoid bubbles between 
strip and SDS-PAGE gel. 8 µl of protein marker was added to a small piece of paper wick. 
1 paper wick was added next to the pH=7 end of the strip. About 2 ml of cooled agarose 
per gel was slowly added across the length of strip to seal the strip and not to trap bubbles. 
Bubbles were dislodged immediately by spatula.  Agarose was waited about 5 minutes to 
cool and solidify. The glass plates were taken out and put into slots. All blank slots were 
filled with blank plates.  The universal buffer-controller (UBC) was covered and put the 
unit into tank. The up chamber was filled with 1L of 2× SDS buffer containing 50 mM 
Tris-Base, 384 mM Glycine, 0.2% (w/v) SDS between “MAX” and “MIN” lines. 1× SDS 
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running buffer was added to the same level. The lid was placed tightly and the protocol 
was programmed as follow to run SDS-PAGE: Step 1 is 2.5 W/gel, 600 V, 400 mA for 
0.5 hr; Step 2 is 10 W/gel for 5-7 hrs. From step 1 to step 2, it was changed manually. 
SDS-PAGE was started to run until the dye front was run near to the bottom.  
2.7.5 Silver Staining 
2.7.5.1 Fixation 
Fresh fixation solution containing 40% (v/v) ethanol, 10% (v/v) acetic acid was prepared 
and mixed well. 250 ml of fixation solution was put into each plastic container. After 
finish running in vertical electrophoresis systems, the SDS-PAGE gels were cut and put 
into individual plastic container. The gels were fixed for more then 12 hrs.  
2.7.5.2 Sensitizing  
Fresh sensitizing solution containing 30% (v/v) Ethanol, 12.7 mM Sodium Thiosulfate, 
0.83 M Sodium Acetate was prepared and mixed well. Fixation solution in the plastic 
container was removed by pipetting with a pump and the SDS-PAGE gels were washed 
with Milli-Q grade water for 2×5 minutes. 250 ml of sensitizing solution was put into the 
plastic container. The gels were incubated in the sensitizing solution for 30 minutes.  
2.7.5.3 Silver Reaction 
Fresh silver reaction solution containing 14.7 mM Silver Nitrate was prepared and mixed 
well and kept at 4ºC refrigerator. Sensitizing solution in the plastic container was 
removed by pipetting with a pump and the SDS-PAGE gels were washed with Milli-Q 
grade water for 3×5 minutes. The gels were incubated with 250 ml of silver reaction 




Fresh developing solution containing 236 mM Sodium Carbonate, 0.04% Formaldehyde 
was prepared and mixed well. Silver reaction solution in the plastic container was 
removed by pipetting with a pump and the SDS-PAGE gels were washed with Milli-Q 
grade water for 2×1 minutes. The gels were developed by incubating with 250 ml of 
developing solution in the plastic container and the process was allowed to take place for 
2-5 minutes.  
2.7.5.5 Stopping 
Fresh stopping solution containing 41 mM EDTA-Na2×H2O was prepared and mixed 
well. Developing solution in the plastic container was removed by pipetting with a pump. 
The developing process of the gels was stopped by adding 250 ml of stopping solution 
into the plastic container and the stopping process was allowed to take place for 10 
minutes. The SDS-PAGE gels were washed with Milli-Q grade water for 3×5 minutes. 
 
2.8 2-DE Data Analysis 
Stained SDS-PAGE gels were sent to be scanned using a GS-800 calibrated imaging 
densitometer (Bio-Rad, Hercules, CA, USA). The data of 2-DE results were analyzed 
using PDQuest (Version 7.2) software (Bio-Rad, Hercules, CA, USA) for protein spot 
quantitation, detection and matching. A master gel was created by the software that 
contained spots data from all the 2-DE gels of both wild type and CD38-deficient splenic 
B cells. Each protein spot was given an integrated OD, which was expressed as ppm of 
total OD, from all valid spots in the gels. The matched protein spots with OD changes by 
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at least two-fold between the wild type and CD38-deficient splenic B cells were selected 
for protein identification. 
 
2.9 Heavy Load of 2-DE  
2-DE was run again with heavy load (500µg per sample) for analyzing by MALDI-TOF 
mass spectrometry (MS). The protocol of heavy load was similar as that of low load 
which was described as above, except that the protocol of first dimension was replaced as 
follow: 200Vx 1.5hrs, 500Vx 2hrs, 4000Vx 3hrs, 8000Vx 7hrs. 
 
2.10 In-Gel Digestion  
2.10.1 Destaining, Washing and Dehydration 
Spots were cut from stained heavy load SDS-PAGE gels according the analyzed data of 
2-DE results and gel spots were cut into fine pieces. A 1:1 ratio of 30mM K4Fe(CN)6  and 
100mM Na2S2O3  was mixed well as working solution. 20-30 µl of working solution was 
added to cover the gel and incubated for 2 minutes with occasional vortexing.  The 
brownish color of the stain was disappeared and then the solution was removed. The gel 
was rinsed with Milli-Q grade water for three times. Subsequently, 100 µl of 100mM 
NH4HCO3 was added to cover the gel and incubated for 20 minutes. After the solution 
was removed, 100 µl of 50mM NH4HCO3/ 50% (v/v) acetonitrile was added and 
incubated for 5 minutes with occasional vortexing and the solution was removed. Again, 
100 µl of 50mM NH4HCO3/ 50% (v/v) acetonitrile was added and incubated for 5 
minutes with occasional vortexing. After the solution was removed, 50 µl of acetonitrile 
was added and incubated for 5 minutes with occasional vortexing and the solution was 
 38
removed carefully. Again, 50 µl of acetonitrile was added and incubated for 5 minutes 
with occasional vortexing and the solution was removed carefully. 
2.10.2 Drying 
The gel was dried in a vacuum centrifuge, e.g. Savant Speed-Vac. 
2.10.3 Digestion 
10-15 µl (enough to cover the gel) of digestion solution (12.5ng/ µl trypsin (Promega, 
Madison, WI, USA) in 50mM NH4HCO3 solution) was added to the gels and incubated 
for 30 minutes. All excess trypsin solution was removed carefully and 15 µl of 50mM 
NH4HCO3 was added and incubated overnight (6-15hrs) in 37ºC oven. 
2.10.4 Extraction 
The gel was allowed to cool down to room temperature and then centrifuged at 6000rpm 
for 10 minutes. Supernatant was removed carefully by pipette and saved in a new tube. 
10 µl of 20mM NH4HCO3 was added to the original tube, mixed and centrifuged at 
6000rpm for 10 minutes. Supernatant was removed carefully by pipette and saved in the 
same tube.  Then 10 µl of 5% formic acid in 50% aqueous acetonitrile was added to the 
original tube and incubated for 5 minutes and centrifuged at 6000rpm for 10 minutes. 
Subsequently, the supernatant was removed carefully by pipette and saved in the same 
tube. The combined supernatant was sent to the Protein and Proteomics Center in the 
Department of Biological Sciences at National University of Singapore for any further 
processing and MALDI-TOF mass spectrometry (MS). Reduction and alkylation steps 




2.11 MALDI-TOF MS 
Samples were sent to Protein and Proteomics Center at Department of Biological 
Sciences, National University of Singapore for further processing and MALDI-TOF MS. 
The simplified steps analyzed by MALDI-TOF MS were as following. Peptide mass 
fingerprint of tryptic peptides were generated by MALDI-TOF MS using a Voyager DE-
STR Biospectrometry work station mass spectrometer (Applied Biosystems, Foster City, 
CA, USA). All spectra were obtained in reflectron mode using a delayed extraction of 
150 ns and an accelerating voltage of 20 kV. Peptide masses were searched against the 
NCBInr database with MS-Fit program (http://prospector.ucsf.edu) and MASCOT 
software (http://www.matrixscience.com). Proteins with a minimum of three matching 
peptides and sequence coverage exceeding 10% with the match proteins, and with a 
probability score of more than 77, were considered positive (Zhao et al., 2005).   
 
2.12 RNA Isolation 
Splenic B cells were isolated from both wild type and CD38 knockout mice using B Cell 
Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according the protocol.  
RNA was isolated from splenic B cells as follow. 
2.12.1 Homogenization 
Splenic B cells were isolated using B Cell Isolation Kit and cell numbers were counted.  
A suitable amount of cell suspension was taken and centrifuged. Cell pellets were lysed 
in TRIZOL Reagent (Invitrogen, Carlsbad, CA, USA) by repetitive pipetting. 1 ml of the 
reagent was used per 5 × 106 splenic B cells.  
2.12.2 Phase Separation 
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Homogenized cell pellets were incubated for 5 minutes at room temperature to permit the 
complete dissociation of nucleoprotein complexes. 0.2 ml of chloroform was added per 1 
ml of TRIZOL Reagent. Sample tubes were capped securely and vigorously shaken by 
hand for 15 seconds and incubated for 2.5 minutes at room temperature. Samples were 
centrifuged at no more than 12,000 ×g for 15 minutes at 4ºC. Following centrifugation, 
the mixture was separated into a lower red, phenol-chloroform phase, an interphase, and a 
colorless upper aqueous phase. RNA remained exclusively in the aqueous phase.  
2.12.3 RNA Precipitation 
The aqueous phase was transferred to a fresh tube and RNA was precipitated from the 
aqueous phase by mixing with isopropyl alcohol. 0.5 ml of isopropyl alcohol was added 
per 1 ml of TRIZOL Reagent used for the initial homogenization. Samples were incubated 
at room temperature for 10 minutes and centrifuged at no more than 12,000 ×g for 10 
minutes at 4ºC. The RNA precipitate, often invisible before centrifugation, formed a gel-
like pellet on the side and bottom of the tube. 
2.12.4 RNA Wash  
The supernatant was removed carefully and the RNA pellet was washed with 75% 
ethanol by adding at least 1 ml of 75% ethanol per 1 ml of TRIZOL Reagent used for the 
initial homogenization. The sample was mixed by vortexing and centrifuged at no more 
than 7,500×g for 5 minutes at 4ºC. 
2.12.5 Redissolving the RNA  
At the end of the procedure, the RNA pellet was briefly dried in air. RNA pellet was 
dissolved in RNase-free water. The RNA concentration was determined by detecting A260 




2.13 Primer Design 
The full protein sequences and complete DNA sequences of identified proteins were 
searched against the NCBI database (http://www.ncbi.blm.nih.gov), according to the 
accession numbers of identified proteins from the MALDI-TOF MS results.  The 
accession number was from the Mascot Search Result by MASCOT software 
(http://www.matrixscience.com). The primers of identified proteins were designed for the 
following RT-PCR by Primer3 software online (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi), according to the complete DNA sequences (CDS) of 
identified proteins. Primers were designed as shown in the following Table 1. 
Table 1 Designed primers  







































2.14.1 First-Strand cDNA Synthesis 
1 µl of Oligo(dT)12-18 (500 µg/ml),  1 µl of dNTP Mix (10 mM each), 4 µl of 5X First-
Strand Buffer; 2 µl of  0.1 M DTT, 0.5 µl of RNase inhibitor,  1 µl of SuperScript™ II 
RT, 1 µg of total RNA and autoclaved, distilled water up to 20 µl were added into 
microcentrifuge tubes.  They were mixed well by pipetting gently up and down and then 
incubated at 42°C for 50 minutes. The reaction was inactivated by heating at 70°C for 15 
minutes. The cDNA was used as a template for amplification in PCR.  
2.14.2 PCR 
5 µl of 10X PCR Buffer (200 mM Tris-HCl, pH 8.4, 500 mM KCl), 3 µl of 25 mM 
MgCl2, 1 µl of 10 mM dNTP Mix, 1 µl of Forward primer (10 µM), 1 µl of Reverse 
primer (10 µM), 0.4 µl of Taq DNA polymerase (5 U/µl), 2 µl of cDNA from first-strand 
reaction and autoclaved, distilled water up to 50 µl were added into microcentrifuge tubes. 
They were mixed well by pipetting gently up and down. PCR was performed in a final 
volume of 50 µl in a Biometra thermocycler (Biometra, Goettingen, Germany) under the 
following conditions: 94°C for 3 minutes denaturing, 30-40 cycles of 94°C for 30 
seconds, 50-60°C  for 30 seconds, 72°C for 30 seconds, and a final extension at 72°C for 
3 minutes.  
 
2.15  Agarose Gel Electrophoresis
2.15.1 Gel preparation 
An adequate volume of electrophoresis buffer (TAE or TBE) was prepared to fill the 
electrophoresis tank. To facilitate visualization of DNA fragments during the run, 
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ethidium bromide solution was added to the electrophoresis buffer to a final 
concentration of 0.5µg/ml. The desired amount of electrophoresis-grade agarose was 
added to a volume of electrophoresis buffer sufficient for constructing the gel (final 
agarose concentration was 1.4%). The agarose was melted in a microwave oven. Gel 
platforms were sealed by taping the open ends with adhesive tape.  Melted agarose was 
cooled with water before pouring onto the gel platform. The melted agarose was poured 
into the gel-casting platform and a gel comb was inserted and bubbles were trapped 
underneath the combs. All bubbles on the surface of the agarose were removed before the 
gel sets.  
2.15.2 Load and run the gel 
After the gel was hardened, the tape was removed from the open ends of the gel platform 
and the gel comb was withdrawn. The gel-casting platform containing the set gel was 
placed in the electrophoresis tank. Sufficient electrophoresis buffer was added to cover 
the gel to a depth of about 1 mm (or just until the tops of the wells were submerged). 
DNA samples were prepared in a volume that would not overflow the gel wells by 
addition of the appropriate amount of 10× loading buffer. Samples were loaded into the 
wells using a pipettor. Appropriate DNA molecular weight markers were also loaded into 
the wells. The leads were attached and the DNA was migrated into the gel toward the 
anode lead. The voltage was set to the desired level, typically 100 V, to begin 
electrophoresis. The progress of the separation was monitored by visualizing the 
migration of dyes (bromophenol blue) in the loading buffer. The separation could also be 
monitored by viewing the gel with a hand-held UV lamp, which induced fluorescence of 
ethidium bound to the DNA fragments in the gel. The power supply was turned off when 
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the dye from the loading buffer was migrated a distance judged sufficient for separation 
of the DNA fragments. The DNA was visualized by placing the gel on a UV light source 
and was photographed directly.  
 
2.16 Visualization of PCR Product  
PCR products were separated on an agarose gel (1.4%) and visualized under UV light 
and photographed. Then photos were scanned and quantified using Gel-Pro Analyzer 
software Version 6.0 (Media Cybernetics, Silver Spring, MD, USA) to determine the 
relative gene expression level.  
2.17 Statistics 
Alterations in optical intensities of all matched protein spots between wild type (n=6) and 
CD38-deficient splenic B cells (n=6) were subjected to two tailed Student’s t-test. Data 















                                                              
Results  
 
3.1 Flow Cytometry 
Resting B cells were isolated from cell suspensions of spleens of both CD38 knockout 
mice and wild type mice by an indirect magnetic labeling system using B Cell Isolation 
Kit (Miltenyi Biotec, Bergisch Gladbach, Germany). Resting B cells isolated by magnetic 
labeling were highly purified since non-B cells were depleted.  Non-B cells, i.e. T cells, 
NK cells, granulocytes, macrophages, dendritic cells, and erythroid cells were indirectly 
magnetically labeled by using a cocktail of biotin-conjugated antibodies against CD43 
(Ly-48), Ter-119, and CD4 (L3T4), as well as Anti-Biotin MicroBeads, which were 
colloidal superparamagnetic MicroBeads conjugated to a monoclonal anti-biotin antibody 
(clone: Bio3-18E7.2; mouse IgG1). Isolation of high pure B cells is achieved by 
depletion of magnetically labeled cells. Biotin-Antibody Cocktail for labeling of non-
target cells and Anti-Biotin MicroBeads were included in B Cell Isolation Kit.           
           
          The highly purified resting B cells were isolated using B Cell Isolation Kit, and the 
purity of isolated B cells was analyzed by flow cytometry. Three samples from a wild 
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type mouse were prepared for analysis. The first sample was from total splenic cells that 
were not isolated by MACS. It was stained with Biotin-Antibody Cocktail and Anti-
Biotin MicroBeads first and then labeled with CD45R (B220)-PE and Anti-Biotin-APC 
(Miltenyi Biotec, Bergisch Gladbach, Germany).  The second sample was from isolated 
splenic B cells. This sample was stained with Biotin-Antibody Cocktail and Anti-Biotin 
MicroBeads first and then labeled with CD45R (B220)-PE and Anti-Biotin-APC.  The 
third sample was also from isolated splenic B cells. This sample was stained with Biotin-
Antibody Cocktail and Anti-Biotin MicroBeads, but not labeled with CD45R (B220)-PE 
and Anti-Biotin-APC.  The analyzed results of the first sample, second sample and third 
sample were shown in the Figure 6A, 6B and 6C, respectively. The density-plotted 
histograms were divided into four areas, as R1, R2, R3 and R4, which were shown in 
Figure 6A, 6B and 6C. The percentages of cells in each area of all the cells were shown 
in the top right corners in Figure 6A, 6B and 6C, respectively.  
           
          Figure 6A, 6B and 6C demonstrated the high purity of isolated splenic B cells from 
a wild type mouse by an indirect magnetic labeling system using B Cell Isolation Kit.  
Obviously, there were two major populations (R1 and R4) of total splenic cells in Figure 
6A. Cells in R1 were mainly APC-labeled non-B cells and cells in R4 were PE-labeled 
CD45+ B cells. A highly enriched population of CD45R+ splenic B cells was obtained in 
R4 (Figure 6B) after isolation by using B Cell Isolation Kit.  Figure 6C showed isolated 
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3.2 2-DE and image analysis 
Six protein samples from wild type and CD38 knockout mice, respectively, were used in 
this project. 80 µg protein of each sample was resolved by 1-D electrophoresis on IPG 
strips and followed by 2-D electrophoresis on SDS-PAGE. After silver staining, similar 
protein patterns were observed on 2-D gels of protein samples from both wild type and 
CD38 knockout mice. The representative results were shown in Figure 7A, 7B, 7C and 
7D. The stained gels were then scanned and analyzed using software (PDQuest version 
7.2). There were about 800 spots consistently detected and matched on all six separate 
gels of each group.  Then 500 µg protein of each sample was resolved by 1-D 
electrophoresis on IPG strips and followed by 2-D electrophoresis on SDS-PAGE. After 
silver staining, several protein spots were cut out from the SDS-PAGE, according to the 
analyzed results.  They were digested by trypsin and then identified by MALDI-TOF MS.  
The protein spots were selected for differential protein expression analysis based on a 
criterion of at least two-fold change in OD and sizes of protein spots in SDS-PAGE. 
          
          About 50 protein spots were significantly altered (p<0.05) in CD38-deficient 
splenic B cells compared with those that were in splenic B cells from wild type mice. 
Totally, 27 protein spots were finally selected and analyzed by MALDI-TOF MS. The 
locations of these 27 selected and analyzed protein spots by MALDI-TOF MS were 
shown in Figure 7C and 7D. 17 protein spots were identified by MALDI-TOF MS and 
summarized in Table 2.  Analyzed 2-DE data of some protein spots were shown as 
representatives in Figure 9.  A master image was in the top left corner in Figure 9A, 9B, 
9C and 9D, respectively. There were six samples from CD38-deficient splenic B cells 
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and wild type splenic B cells, respectively (Figure 9). The protein (shown in the square of 
the master image) was identified as β-globin, which was up-regulated in the CD38-
deficient splenic B cells (Figure 9A). The protein (shown in the square of the master 
image) was identified as Sgt1, a suppressor of the G2 allele of Skp1, which was down-
regulated in the CD38-deficient splenic B cells (Figure 9B). The protein (shown in the 
square of the master image) was not identified, which was up-regulated in the CD38-
deficient splenic B cells (Figure 9C). The protein (shown in the square of the master 
image) was not identified, which was down-regulated in the CD38-deficient splenic B 
cells (Figure 9D). The two proteins identified by MALTI-TOF MS are also shown in 
Table 2. 
           
          In the identified proteins, a few were dramatically (>290-fold) altered in their 
expression levels in CD38-deficient splenic B cells. These include acidic nuclear 
phosphoprotein pp32 (No. 8047), chitinase-related protein MCRP (No. 7134), β-globin 
(No. 6103) and one unnamed protein (No. 3503).  For example, the mean OD value of the 
protein (No. 8047) was 217.6269 in the group of wild type splenic B cells, whereas it was 
only 0.7189 in the group of CD38-deficient splenic B cells. It meant that the expression 
of this protein was down-regulated by 302.72-fold in CD38-deficient splenic B cells. 
Fold-changes of identified proteins were calculated according to their average OD values 
in both groups of wild type and CD38-deficient splenic B cells. They are shown in Table 
2. The expression levels of the rest of the identified proteins were changed by 2~45-fold 
in CD38-deficient splenic B cells.  
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          Among the 17 identified proteins, 9 proteins were up-regulated in the CD38-
deficient splenic B cells.  They were malate dehydrogenase (No. 1327), peroxiredoxin 6 
(Prdx6) (No. 3101), β-globin (No. 6103), sorting nexin 5 (No. 1509), coactosin-like 1 
(No. 7003), hydroxypyruvate isomerase homolog (No. 3104), S-adenosylhomocysteine 
hydrolase (No. 1417) and two novel proteins (No. 4213 and 3503). In contrast, eight 
proteins were down-regulated in the CD38-deficient splenic B cells. They were SGT1 
(No. 4332), chitinase-related protein MCRP (No. 7134), Ym1 (No. 4424), acidic nuclear 
phosphoprotein pp32 (No. 8047), immunoglobulin (CD79A) binding protein 1 (No. 
3405), myo-inositol 1-phosphate synthase A1 (No. 1732) and two unnamed proteins (No. 
8613 and 8203).  They are listed in the Table 2. 
            
           The locations of these 17 identified protein spots were shown in a master image 
(Figure 8). This 2-DE reference map was composed of dataset of 12 gels (n=6 for wild 
type splenic B cells and n=6 for CD38-deficient splenic B cells). The numbers 
represented the spot identification numbers listed in Table 2, which were generated 
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Figure 7 Representative 2-D gels of proteins from wild type (A, C) and CD38-deficient 
splenic B cells (B, D). The locations of these 27 selected and analyzed protein spots by 
MALDI-TOF MS were shown in (C and D). Proteins of both wild type and CD38-
deficient splenic B cells were separated by 2-DE using IPG at pH 4–7 and 12% SDS-
PAGE. Proteins were stained with silver nitrate. 
 
 




























Figure 8 Differential protein expression profile between wild type and CD38-deficient 
splenic B cells was in a master image. 2-DE reference map was composed of dataset of 
12 gels (n=6 for wild type splenic B cells and n=6 for CD38-deficient splenic B cells). 
Proteins were separated by two dimensional electrophoresis using IPG at pH 4-7. 
Proteins were identified by peptide mass mapping by MALDI-TOF MS. The numbers 
represent the spot identification numbers listed in Table 2, which were generated during 
analysis by PDQuset software. Note: the position of this image was 180º reversed 
compared with those in Figure 7.  The position of this image was created by software and 





   
Master 
     WT mouse 6       WT mouse 5   WT mouse 4 
         WT mouse 3      WT mouse 1                WT mouse 2   CD38 KO mouse 5        CD38 KO mouse 6 







   A.                                                                        
  
   B. 
  Master 
     WT mouse 4
Figure 9 Rep
The master im
in the square 
the CD38-def




      CD38 KO mouse 1       WT mouse 5
resentatives of 
age was in the
of the master i
icient splenic 
identified as Sg
 two proteins i   CD38 KO mouse 2    WT mouse 1 
      WT mouse 6
analyzed 2-DE
 top left corne
mage) was iden
B cells. (B) Th
t1, which was 
dentified by M    CD38 KO mouse 3   WT mouse 2   
 
 data.  




ALTI-TOF MS aD38 KO mouse 4         WT mouse 3 CD38 KO mouse 5 CD38 KO mouse 6   
 D). (A) The protein (shown 
n, which was up-regulated in 
 in the square of the master 
in the CD38-deficient splenic 
re also shown in Table 2. 
54
         
CD38 KO mouse 4 Master   CD38 KO mouse 1    CD38 KO mouse 2 CD38 KO mouse 3
CD38 KO mouse 5 CD38 KO mouse 6    WT mouse 1     WT mouse 2      WT mouse 3 
     WT mouse 4      WT mouse 5       WT mouse 6 
  C.                                                                         
   
   CD38 KO mouse 4     CD38 KO mouse 1 CD38 KO mouse 2 CD38 KO mouse 3
     Master 
CD38 KO mouse 5 CD38 KO mouse 6       WT mouse 1 WT mouse 2      WT mouse 3 
     WT mouse 4       WT mouse 5       WT mouse 6 
  D. 
Figure 9 Representatives of analyzed 2-DE data.  
The master image was in the top left corner in (A, B, C and D). (C) The protein (shown in 
the square of the master image) was not identified, which was up-regulated in the CD38-
deficient splenic B cells. (D) The protein (shown in the square of the master image) was 





Table 2 Identified proteins with significant expression level changed in CD38-deficient 
splenic B cells. 




6103 β-globin gi|4760590 109 54 773.84 
7134 chitinase-related 
protein MCRP 
gi|1336166 170 21 -317.78 
8047 acidic nuclear 
phosphoprotein pp32
gi|1763275 100 12 -302.72 
3503 unnamed protein 
product 
gi|74151629 122 26 292.91 
4332 Sgt1 gi|23956176 80 28 -45.58 
3101 Peroxiredoxin 6  gi|38174148 393 62 7.28 
3104 Hydroxypyruvate 
isomerase homolog 
gi|19354263 119 32 5.77 
1327 malate dehydrogenase gi|56206644 287 35 4.99 
8613 unnamed protein 
product
gi|74223209 83 21 -4.08 
7003 coactosin-like 1 gi|19482160 186 32 3.70 
3405 Immunoglobulin 
(CD79a) receptor 
binding protein 1 (α4) 
gi|51479181 127 24 -3.52 
4213 unnamed protein 
product 
gi|12848275 365 37 3.42 
8203 unnamed protein 
product 
gi|26341416 278 48 -2.80 
1509 sorting nexin 5  gi|18034769 308 41 2.46 




gi|61098092 403 33 2.11 
1732 myo-inositol 1-
phosphate synthase A1 
gi|12963757 160 14 -2.04 
 
a. Score is -10*Log(P), where P is the probability that the observed match is a random 
event. Protein scores >77 are significant (p<0.05). 
b. Coverage refers to peptide sequence homology of at least 10% to the matched protein. 
c. Fold-changes are >2 fold in CD38-deficient splenic B cells. 





RT-PCR was conducted on selected identified proteins for verifying the 2-DE results. 
Primers were designed and RT-PCR was performed as described in Materials and 
Methods. Total RNA samples were from splenic B cells of three wild type and three 
CD38 knockout mice, respectively. All experiments were repeated more than three times 
with similar pattern of results. Sgt1, a suppressor of the G2 allele of Skp1, was shown as 
a representative of all selected identified proteins in Figure 10. From the results, the 
protein expression levels of Sgt1 were higher in wild type splenic B cells than those in 
CD38-deficient splenic B cells (Figure 10A).  At the same time, the mRNA expression 
levels of Sgt1 in wild type splenic B cells were higher than those in CD38-deficient 
splenic B cells (Figure 10B). Therefore, the mRNA expression levels of Sgt1 were 
consistent with protein expression levels of Sgt1. 
            
          The 2-DE and RT-PCR results of other selected identified proteins were showed in 
Figure 11. From the results, the mRNA expression levels of malate dehydrogenase were 
consistent with the protein expression levels of malate dehydrogenase in wild type and 
CD38-deficient splenic B cells. Both mRNA and protein expression levels of malate 
dehydrogenase were higher in CD38-deficient splenic B cells than those in wild type 
splenic B cells.  The mRNA expression levels of Prdx6 were consistent with the protein 
expression levels of Prdx6 in wild type and CD38-deficient splenic B cells. Both mRNA 
and protein expression levels of Prdx6 were higher in CD38-deficient splenic B cells than 
those in wild type splenic B cells. The mRNA expression levels of hydroxypyruvate 
isomerase homolog were consistent with the protein expression levels of 
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hydroxypyruvate isomerase homolog in wild type and CD38-deficient splenic B cells. 
Both mRNA and protein expression levels of hydroxypyruvate isomerase homolog were 
higher in CD38-deficient splenic B cells than those in wild type splenic B cells.     
However, the mRNA expression levels of β-globin were inconsistent with its protein 
expression levels. The mRNA expression levels of β-globin were the same in both wild 
type and CD38-deficient splenic B cells, whereas the protein expression levels of β-
globin were higher in CD38-deficient splenic B cells than those in wild type splenic B 
cells (Figure 11). 
            
          In addition, the mRNA expression levels of CD38 were tested. From the results, 
the mRNA expression levels of CD38 were higher in wild type splenic B cells, while 
there were no mRNA expression levels of CD38 in CD38-deficient splenic B cells.  The 
results confirmed the deficiency of CD38 mRNA in CD38 knockout mice. Furthermore, 
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Figure 10 2-DE and RT-PCR results of Sgt1  
(A) The locations and protein spots of Sgt1 in three randomly selected 2-D gels of protein 
samples from wild type and CD38-deficient splenic B cells were shown. (B) RT-PCR 
results of Sgt1 and β-actin gene expression levels in three RNA samples from wild type 
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Figure 11 RT -PCR and 2-DE data of selected identified proteins                      
The locations and protein spots of malate dehydrogenase, Prdx6, hydroxypyruvate 
isomerase homolog and β-globin in three randomly selected 2-D gels of protein samples 
from wild type and CD38-deficient splenic B cells were shown. RT-PCR analyses of 
splenic B cells from three wild type and three CD38 knockout mice targeting at gene 
expression of proteins that were found to have significantly altered expression levels in 
CD38-deficient splenic B cells by 2-DE. Only β-globin gene expression levels were 
inconsistent with its protein expression levels. In addition, RT-PCR products of CD38 
confirmed the deficiency of CD38 mRNA in CD38 knockout mice. Methods of RT-PCR 
were described in detail in the part of materials and methods. Experiments were repeated 
more than three times with similar pattern of results. 












                                            




4. Discussion and Conclusion 
 
CD38 has been found for more than two decades since then there are many researchers 
studying on it. We have known that CD38 plays pivotal roles as a multifunctional 
ectoenzyme. CD38 can catalyze the synthesis of cADPR and NAADP, two structurally 
distinct Ca2+-mobilizing molecules (Lee et al., 1997). It is a surface receptor in B cells.  
The functional relationships between CD38 and BCR suggest that the signaling pathways 
utilized by CD38 and BCR may intersect (Lund et al., 1996). Furthermore, CD38 is 
related to certain human diseases. However, the functional significance of CD38 
expression on B cells is not well understood yet (Lund et al., 2006).  This is the first 
study to analyze the differential protein profiles of B cells using CD38 knockout and wild 
type mice. Seventeen differentially expressed proteins in CD38-deficient splenic B cells 
were identified by MALDI-TOF MS. From the previous studies, these identified proteins 
might provide new insights into the functional roles of CD38 in certain human diseases.  
           
           Zupo et al. (1996) have reported that B-chronic lymphocytic leukemia (B-CLL) 
patients can be subdivided into two different groups, CD38-positive type B-CLL and 
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CD38-negative type B-CLL, depending on the presence or absence of CD38 on the 
malignant cells. Moreover, exposure of these malignant cells with high CD38 expression 
in vitro to anti-µ antibodies resulted in calcium mobilization followed by apoptosis, while 
neither of these phenomena was observed in the CD38-negative cells. In this study, we 
observed immunoglobulin (CD79a) receptor binding protein 1 (also known as α4 protein) 
was down-regulated in the CD38-deficient B cells. CD79a, a B-cell surface molecule 
closely associated with immunoglobulins, is expressed during the entire span of B-cell 
development. CD79a is involved in the mediation of intracellular signal transduction after 
antigen binding in B cells through this interaction. α4 protein is broadly expressed, 
including B cells (Inui et al., 1995). It is a regulator of the dephosphorylation of 
transcription factors p53 and c-Jun (Chuang et al., 2000; Kong et al., 2004). Multiple 
proapoptotic genes have been known to be up-regulated as a result of α4 protein 
deficiency (Kong et al., 2004). α4 protein is known to mediate BCR signals and required 
for B cell maturation (Inui et al., 2002). α4 protein might be a key factor when CD38 
plays a role in apoptosis.  Moreover, we found that pp32 was drastically down-regulated 
in the CD38-deficient B cells.  pp32 belongs to a family of leucine-rich acidic nuclear 
proteins which play important roles in transcription, RNA transport, regulation of 
chromatin remodeling, transformation and apoptosis (Fan et al., 2006). It can specifically 
bind to histone H3 and block its phosphorylation and acetylation (Fan et al., 2006). pp32 
promotes granzyme A-mediated caspase-independent cell death and directly initiates 
caspase activity (Fan et al., 2006). Taken together, pp32 is able to play a repressive role 
by inhibiting transcription and triggering apoptosis (Fan et al., 2006). Thus, pp32 might 
also be an intermediate between CD38 and apoptosis.  Additionally, our study showed 
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that Sgt1 was substantially down-regulated in CD38-deficient B cells. Sgt1, a suppressor 
of the G2 allele of Skp1, plays a role in the Skp1-Cul1-F-box protein (SCF) ubiquitin 
ligase and the centromere-binding factor 3 (CBF3) kinetochore complexes (Spiechowicz 
and Filepek, 2005). Steensgaard et al. (2004) have reported that RNA interference-
mediated depletion of Sgt1 in HeLa cells caused dramatic alterations of the mitotic 
spindle leading to mitotic delay due to the activation of spindle checkpoint. Recently, 
Ludwig et al. (2005) found that cell death occurred in non-silenced Sgt1 control plant 
leaves, while no necrosis developed on plant leaves when the Sgt1 was silenced. Thus, 
Sgt1 might be able to clarify how CD38 can trigger cell death. This might be a good 
explanation why exposure of these malignant cells with high CD38 expression in vitro to 
anti-µ antibodies resulted in calcium mobilization followed by apoptosis, while neither of 
these phenomena was observed in the CD38-negative cells. Thus, the three proteins 
might be potential targets for future study on the causal relationships between CD38 and 
apoptosis, as well as B-CLL.  
            
          Previously, it was observed that CD8+ T cells have an increased expression of 
CD38 in human immunodeficiency virus type 1 (HIV-1)-infected patients (Bofill et al., 
1996). Therefore, some researchers used CD38 as a useful and reliable prognostic marker 
for the pathological development of AIDS (Liu et al., 1998). Recently, Onlamoon et al. 
(2005) have found that the most discriminating change between healthy donors and HIV-
1-infected patients is the increased frequency and density of CD38 expression by 
CD3+CD8+ T cells. We found that S-adenosylhomocysteine hydrolase was increased in 
CD38-deficient B cells. S-adenosylhomocysteine hydrolase can convert S-
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adenosylhomocysteine to homocysteine and adenosine in mammalian cells, and S-
adenosylhomocysteine is a product from S-adenosylmethionine (Greenberg et al., 1989). 
Studies of S-adenosylmethionine utilization in vitro suggest that lymphocytes may have a 
greater requirement for transmethylation than other cell types, so that diminished S-
adenosylhomocysteine hydrolase activity may be particularly detrimental to immune 
function (Greenberg et al., 1989).  From our results, we can conclude that an increased 
expression of CD38 diminishes S-adenosylhomocysteine hydrolase activity. S-
adenosylhomocysteine hydrolase might be able to explain the phenomenon that CD8+ T 
cells have an increased expression of CD38 in HIV-1-infected patients. Moreover, our 
data showed that peroxiredoxin 6 (Prdx6) was increased in the CD38-deficient B cells. 
Prdx6 is a member of peroxiredoxins family. Peroxiredoxins are highly conserved 
antioxidant enzymes. They have two subfamilies that one subfamiliy uses 1-Cys and the 
other uses 2-Cys to scavenge reactive oxygen species (ROS).  Prdx6, the only 1-Cys 
member, is a bifunctional protein with both phospholipase A2 (PLA2) and Glutathione 
(GSH) peroxidase activities (Manevich and Fisher, 2005). Prdx6 uses GSH as an electron 
donor to reduce H2O2 and other hydroperoxides, including phospholipid hydroperoxides 
(Manevich and Fisher, 2005).  Peroxiredoxins are capable of protecting cells from ROS 
insult and inhibiting human immunodeficiency virus (HIV) infection. They can regulate 
the signal transduction pathways that utilize caspases, c-Abl, nuclear factor-kappaB (NF-
kappaB) and activator protein-1 (AP-1) to influence cell growth and apoptosis. From our 
data, we can deduce that Prdx6 is decreased in cells that have high expression of CD38. 
Furthermore, it can be concluded that those CD8+ T cells having an increased expression 
of CD38 in HIV-1-infected patients have less ability to protect cells from ROS insult and 
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inhibit HIV infection.  Thus, these two proteins might be able to explain why CD8+ T 
cells have an increased expression of CD38 in HIV-1-infected patients.  
            
          CD38 was shown to play a pivotal regulatory role in the murine model with regards 
to insulin secretion through calcium mobilization of cADPR-sensitive stores (Kato et al., 
1995). The study on the causal relationship between insulin release and CD38 has been 
extrapolated to man where it is shown that anti-CD38 autoantibodies may play an 
important role in impaired glucose-induced insulin secretion (Ikehata et al., 1998). 
Moreover, Yagui et al. (1998) have shown that the Arg140Trp mutation on CD38 may be 
responsible for the development of Type II diabetes mellitus through the impairment of 
glucose-induced insulin secretion. Kato et al. (1999) have corroborated the growing 
evidence that CD38 is essential in intracellular Ca2+-mobilization via cADPR for the 
secretion of insulin through experiments using CD38 knockout mice.  Recently, Mallone 
et al. (2002) have shown that anti-CD38 autoantibody prevalence among new-onset Type 
I diabetic patients was lower than previously found in long-standing Type I diabetes, 
suggesting a late appearance of these autoantibodies. In this study, we found that malate 
dehydrogenase was increased in CD38-deficient B cells. Malate dehydrogenase plays an 
important role in the malate–aspartate shuttle and is a positive regulator of the transfer of 
NADH, and ATP production in mitochondria. Thus, malate dehydrogenase is considered 
as one of important enzymes in the energy metabolic conditions in tissues. A remarkable 
decrease in malate dehydrogenase activities was observed in some types of peripheral 
leukocytes of dogs and cats with type 1 diabetes mellitus. Moreover, intrinsically lower 
and further decreased malate dehydrogenase activities may induce insulin resistance 
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observed in diabetic cats (Magori et al., 2005). Thus, malate dehydrogenase might be an 
intermediate in the causal relationship between CD38 and diabetes.  In addition, we 
found that β-globin was dramatically up-regulated in the CD38-deficient B cells. β-globin 
is a member of the globin family in vertebrates and may play a role in oxidative stress in 
diabetic patients.  Lapolla et al. (2004) found that β-globin was glycated and glyco-
oxidated in diabetic patients. From our results, it can be deduced that CD38 may inhibit 
expression of both malate dehydrogenase and β-globin in normal B cells. We extrapolate 
that CD38 also can play functional roles in diabetic patients through regulating 
expression of malate dehydrogenase and β-globin. CD38 may play roles in diabetes 
mellitus through different pathways. 
           
          The poor prognosis of myeloma has prompted the use of alternative treatments 
including hormonotoxins and immunotoxins. However, the use of modified toxins 
conjugated to hormones or antibodies to surface molecules on myeloma cells is hampered 
by the lack of specific targets on plasma cells. An interesting alternative method used the 
increased expression of CD38 in these myeloma cells as a target for the in vitro and in 
vivo depletion of tumor cells (Ellis et al., 1995). Stevenson et al. (1991) reported that 
recombinant anti-CD38 mAb with a murine anti-CD38 variable region mounted on a 
human IgG Fc sequence cross-linked to a modified ricin molecule. Furthermore, an 
alternative approach entailed the use of bispecific antibodies for the delivery of other 
toxins in human acute T cell lymphoblastic leukemia through CD7 and CD38 as target 
molecules (Flavell et al., 1992). CD22 and CD38 as target molecules for bispecific 
antibodies in the immuno-treatment of lymphoma have also been used (French et al., 
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1995). Moreover, Flavell et al. (1995) reported that a similar approach was tested for the 
treatment of B-cell lymphoma using anti-CD-19 and anti-CD38-saponin immunotoxins. 
The results obtained from these studies suggest that anti-CD38-toxin immunoconjugates 
might prove to be useful therapeutic tools in the treatment of myeloma, lymphoma and 
leukemia. In each case, the toxic potential on tumor cells with higher expression of CD38 
was significant, whereas effects on normal peripheral blood cells or hematopoietic 
progenitor cells were negligible (Mehta et al., 1996).  Recently, Bolognesi et al. (2005) 
have reported that it is reasonable to propose a clinical use of the IB4/saporin-S6 for ex 
vivo purging of unwanted cells (e.g. CD38+ neoplastic cells from a Non Hodgkin 
Lymphoma patient) or for loco-regional therapies of CD38+ tumors. In this study, we 
found that Myo-inositol 1-phosphate synthase A1 (ISYNA1) was decreased in CD38-
deficient B cells. ISYNA1 can convert glucose-6-phosphate to myo-inositol 1-phosphate, 
which is then converted to myo-inositol by myo-inositol monophosphatase-1 and 2 
(IMPA1, IMPA2) (Seelan et al., 2004). ISYNA1 thus catalyzes the first step in the 
synthesis of all inositol containing compounds, including phospholipids (Seelan et al., 
2004). These compounds play important roles in several biological processes: acting as 
critical second messengers in signal transduction pathways, serving as key components of 
cellular membranes, and playing a role in chromatin remodeling and gene transcription 
(Seelan et al., 2004).  Besides, our data showed that sorting nexin 5 (SNX5) was 
increased in CD38-deficient B cells. SNX5 is a member of a large family of proteins that 
contain the phosphoinositide-binding Phox homology (PX) domain (Merino-Trigo et al., 
2004). SNX5 can bind to phosphatidylinositol 3-phosphate (PtdIns(3)P), which mediates 
their localization to membranes of the endocytic pathway (Merino-Trigo et al., 2004). 
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Overexpression of SNX5 has been shown to inhibit the degradation of endosomally 
transported epidermal growth factor (EGF) receptors (Liu et al., 2006). We also found 
that coactisin-like 1 was increased in CD38- deficient B cells. Coactosin-like 1 belongs 
to the actin depolymerizing protein superfamily. It shares high homology with coactosin, 
a filamentous (F)-actin binding protein, and interacts with 5-lipoxygenase and F-actin (Li 
et al., 2004). Depolymerization of actin enhances BCR signaling, leading to lipid raft 
clustering, extracellular signal related kinase (ERK) activation, and transcription factor 
activation (Hao and August, 2005).  From our data, CD38 may play vital roles in signal 
transduction pathways, endocytic pathways, ERK and transcription factor activations 
through regulating ISNYA1, SNX5 and coactosin-like 1, respectively. These results 
might be able to illuminate that CD38 could be used an important target in the clinical 
therapies for myeloma or CD38+ tumors. 
            
          Recently, it has been demonstrated that CD38-cADPR-mediated calcium signaling 
contributes to airway smooth muscle (ASM) hyper-responsiveness. Airway hyper-
responsiveness, defined as increased reactivity of airways to spasmogens, is a key feature 
of airway inflammation. Smooth muscle is the target of many inflammatory diseases, 
such as asthma, since it is the principal contractile component of airways (Deshpande et 
al. 2005).  Moreover, Tliba et al. (2004) have demonstrated that interferon-β-dependent 
activation of CD38 pathway is a novel pathway, by which tumor necrosis factor-α (TNFα) 
induces CD38 expression and regulates gene expression in human ASM cells. CD38 may 
play a role in cytokine-induced airway smooth muscle (ASM) cell hyper-responsiveness 
which is a key feature associated with chronic asthma (Tliba et al., 2004). In this study, 
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we found that Ym1 was reduced in CD38-deficient B cells.  Ym1 is a member of a family 
of mammalian proteins sharing homology to chitinases of lower organisms. Ym1 may 
have a defensive role by binding fungal or other pathogens containing chitin, but it has no 
apparent chitinase activity. Its effector mechanisms remain unclear and these mechanisms 
may include the sequestration of the pathogens and/or the recruitment of effector immune 
cells. Ym1 may also mediate cell-to-cell and cell-to-matrix interactions in a manner 
similar to that of selectins, through its ability to bind heparin, a glycan abundant on the 
cell surface and the extracellular matrix.  A role in the deposition of extracellular matrix 
during the wound-healing process has been proposed. And Ym1 has been identified in a 
variety of Th2-mediated inflammatory settings (Nair et al., 2005). We also found that 
murine chitinase-related protein (MCRP) was decreased dramatically in CD38-deficient 
B cells. MCRP is a member of chitinase-like proteins and chitinases are endo-b-1, 4-N-
acetylgluco-samidases. In lower life forms, chitinases are produced in significant 
quantities by hosts defending against infections with chitin-containing organisms. It may 
be part of the innate immune response against a chitin-containing pathogen. Chitinase 
production plays a key role in the life cycle of chitin-containing fungi and parasites and 
can be used by pathogens to invade chitin-containing structures to complete their life 
cycle in the host. MCRP has been noted to be induced during Th2 inflammation through 
an IL-13–dependent mechanism (Elias et al., 2005).  It has an important role in the 
pathogenesis of Th2 inflammation and in IL-13 effector pathway activation (Elias et al., 
2005). MCRP was expressed in an exaggerated fashion in human asthmatic lung tissues 
(Elias et al., 2005). From our results, we can deduce that the expression of both Ym1 and 
MCRP are increased in normal B cells or CD38+ cells, which may give additional 
 69
evidence that CD38 plays a role in inflammatory diseases, such as asthma. CD38 may 
play a role in asthmatic patients through promoting chinitase-related proteins, such as 
Ym1 and MCRP, in CD38+ cells.   
          
          In this study, we also found that hydroxypyruvate isomerase homolog was 
increased in CD38-deficient B cells. It is a homolog of hydroxypyruvate isomerase, 
which has been identified in E.coli. However, the function of hydroxypyruvate isomerase 
is still unclear. Hydroxypyruvate isomerase has not been identified in eukaryotes 
(Ashiuchi and Misono, 1999). Our result may be the first time that hydroxypyruvate 
isomerase homolog has been identified in murine B cells, which may provide insights 
into the function of hydroxypyruvate isomerase. In addition, we identified four novel 
proteins (No.3503, 8613, 4213 and 8203, shown in Figure 7C, 7D and 8), whose 
expression is altered as a consequence of CD38 deficiency in B cells. Their functions are 
still not known, but the results may provide more knowledge of the functions of CD38 in 
cells.  
   
          Intriguingly, CD38 was not identified by MALDI-TOF MS as one of the proteins 
with altered expression between the wild type and CD38 knockout mice. This could be 
due to the fact that CD38 is a low abundance protein and its low density level in the crude 
extract of splenic B cells may be beyond the detection limit of 2D-gel electrophoresis. In 
addition, we only ran the whole proteins of isolated splenic B cells in pH4-7 IPG strips.  
This might be another reason why CD38 was not identified by MALDI-TOF MS if 
CD38’s PI was above 7. Furthermore, CD38 might be in those unidentified proteins that 
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were significantly altered (p<0.05) in CD38-deficient splenic B cells. In addition, β-
globin was identified dramatically increased in CD38-deficient B cells. However, β-
globin is usually in red blood cells. It was interesting that β-globin was identified in B 
cells. Maybe, our purified splenic B cells were contaminated with red blood cells. In fact, 
other groups also identified β-globin in B cells (data not shown), although it was very 
uncommon that β-globin was expressed highly in B cells.  
            
          In addition, the results of RT-PCR confirmed the lack of CD38 in CD38 knockout 
mice. However, we should use quantitative Real-Time PCR to confirm all of the results 
of our identified proteins. It was a shortcoming in this project that we only used RT-PCR 
since we thought it was enough according to Zhao et al. (2005) at that time. Actually, we 
tried to publish the data of this project and realized this defect through reviewing 
comments from reviewers of a journal.  At the same time, one of the reviewers confirmed 
our suspicion that there was a big defect in this project. We used CD-1 mice to cross with 
CD38 knockout mice. Also we used CD-1 mice as controls. However, CD-1 mice are an 
outbred strain and derived from Swiss mice that have a high degree of genetic variation.  
This meant that genetic backgrounds might be highly different between CD-1 mice and 
CD38 knockout mice. That is to say, CD38 might not play the vital role of inducing the 
differential protein profiles of B cells between CD38 knockout and wild type mice. The 
different genetic backgrounds between CD38 knockout and wild type mice might play 
the pivotal roles. Therefore, it was no useful for us to perform quantitative Real-Time 
PCR to confirm the results of all of our identified proteins.  In fact, this project was only 
a part of my work. It was mainly completed in my first year (Aug 2004-July 2005) at 
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National University of Singapore.  In addition, I worked on another project on proteomic 
analysis of B cells from OVA-treated wild type and CD38 knockout mice. I had already 
completed the major part (2-DE) of that project when we knew the big defect in our mice. 
In the following months, I discussed the problem with my supervisors. Finally, we 
reluctantly made a decision to stop the project immediately and began to use C57BL/6J 
mice to intercross with CD38 knockout mice. C57BL/6J mice are an inbred strain. 
C57BL/6J mice are appropriate mice to study in this project. Usually, a mutation 
typically is crossed onto the C57BL/6J background for 10 generations, at which point it is 
considered congenic since the genome is expected to be 99.8% C57BL/6J. It will take 
about more than 1.5 years to generate mice and I cannot wait for such a long time to 
repeat similar projects. Therefore, I made a decision to stop my further study towards a 
PhD degree at this stage. 
 
            In conclusion, the project would have been very interesting if we had generated 
and used appropriate mice, but we used inappropriate mice and the results we got in this 
project are not conclusive. From our data, CD38 might be a multi-functional molecule in 
murine B cells. This study might reveal novel information on the possible functional roles 
of CD38 in B cell immune responses, which might open new directions for future studies 
of B cell signaling, apoptosis and proliferation. However, the results might make no sense 
if the different genetic backgrounds between mice played the pivotal roles of inducing the 
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